fluorodeoxyglucose f18 has been researched along with Melanoma in 547 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.18) | 18.7374 |
| 1990's | 35 (6.40) | 18.2507 |
| 2000's | 183 (33.46) | 29.6817 |
| 2010's | 223 (40.77) | 24.3611 |
| 2020's | 105 (19.20) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, JY; Karikios, D; Lee, ME; Mansberg, R; Parry, NM | 1 |
| Cachin, F; De Leiris, N; Flaus, A; Habouzit, V; Leccia, MT; Perrot, JL; Prevot, N; Vuillez, JP | 1 |
| Baijens, LWJ; Krebbers, I; Kunst, HPM; van den Hout, MFCM; Waterval, JJ | 1 |
| Abgral, R; Salaun, PY; Sassolas, B | 1 |
| Amaya, S; Minami, T; Mitsui, T; Munemoto, Y; Nakanuma, Y; Saito, K; Shimada, M; Takashima, Y; Terada, T; Yamagishi, Y | 1 |
| Bagni, O; Filippi, L; Potenza, C; Proietti, I; Schillaci, O | 1 |
| Carlino, MS; Dimitriou, F; Emmett, L; Kapoor, R; Lo, SN; Long, GV; Menzies, AM; Tan, AC | 1 |
| Nimmagadda, S | 1 |
| Chen, L; Cornelius, LA; Fields, RC; Jaeger, ZJ; Mhlanga, JC; Williams, GA | 1 |
| Annovazzi, A; Carpano, S; Ferraresi, V; Rea, S; Renna, D; Russillo, M; Sciuto, R | 1 |
| Abbatepaolo, C; Arezzo, F; Bellitti, E; Cazzato, G; Cimmino, A; Colagrande, A; Cormio, G; Foti, C; Ingravallo, G; Lettini, T; Loizzi, V; Lospalluti, L; Resta, L; Romita, P; Rossi, R; Sablone, S | 1 |
| Aide, N; Alipour, R; Hicks, RJ; Iravani, A; Kottler, D; Prigent, K | 1 |
| Andersen, R; Donia, M; Ellebaek, E; Hendel, HW; Schina, A; Svane, IM | 1 |
| Kang, F; Niu, J; Quan, Z; Wang, J; Zhao, X | 1 |
| Barbato, F; Chorti, E; Fendler, WP; Ferdinandus, J; Grünwald, V; Herrmann, K; Livingstone, E; Schadendorf, D; Seifert, R; Ugurel, S; Umutlu, L; Zaremba, A; Zimmer, L | 1 |
| Andersen, JAS; Bastholt, L; Gerke, O; Grupe, P; Hess, S; Hildebrandt, MG; Holdgaard, PC; Spatzek, AD; Vilstrup, MH | 1 |
| Antke, C; Emil, N; Giesel, FL; Lawal, I; Mokoala, K; Sathekge, M | 1 |
| Garland-Kledzik, M; Hamilton, O; Likar, C; Thomay, A; Williams, A | 1 |
| Aalbersberg, EA; Blankenstein, SA; Haanen, JB; Klop, WMC; Stokkel, MPM; van Akkooi, ACJ; van de Wiel, BA; van der Hiel, B; Wondergem, M | 1 |
| Lan, X; Li, M; Zhang, X | 1 |
| Alçin, G; Beyhan, E; Cermik, TF; Erol Fenercioglu, Ö; Sengul Samanci, N; Tatar, G | 1 |
| Abouzian, S; Camacho, V; Carrió, I; Duch, J; Estorch, M; Fernández-León, A; Flotats, A; López-Mora, DA; Sabaté-Llobera, A; Sampedro, F; Sizova, M; Stefaneli, P | 1 |
| Blanchet, K; Bodet-Milin, C; Carlier, T; Dréno, B; Frenard, C; Khammari, A; Lecerf, P; Sebille, JC | 1 |
| Bayat, M; Doroudinia, A; Karam, MB; Mehrian, P | 1 |
| Arnold, A; Hohmann, J; Weber, P | 1 |
| Isenborghs, E; Michielin, O; Schaefer, N; Testart Dardel, N; Valerio, M | 1 |
| Bastholt, L; Bidstrup, PE; Bojesen, S; Chakera, AH; Ellebæk, E; Helvind, NM; Hendel, HW; Hölmich, LR; Johansen, C; Kjærskov, MW; Petersen, SK; Skyum, H; Svane, IM; Weitemeyer, MB | 1 |
| Berberich, C; Gaa, J; Krackhardt, A; Mustafa, M; Nekolla, SG; Zhuwu, Y | 1 |
| Christopoulos, P; Dimitrakopoulou-Strauss, A; Hassel, JC; Sachpekidis, C | 1 |
| Dimitriou, F; Ensle, F; Huellner, MW; Maurer, A; Schaab, JA | 1 |
| Ding, H; Fan, D; Huang, Z; Liu, Y; Wan, Z | 1 |
| Li, X; Wu, H; Zhou, W | 1 |
| Abernethy-Leinwand, A; Bouchard, DM; Collichio, FA; Ezzell, JA; Giglio, BC; Googe, PB; Ivanova, A; Ivanovic, M; Kowalski, MH; Lee, YZ; Li, Z; Long, PK; Meyers, MO; Moschos, SJ; Nikolaishvili-Feinberg, N; Oldan, JD; Ollila, DW; Smith, E; Thomas, NE; Trembath, DG; Wallack, DE; Wong, TZ; Zhao, W | 1 |
| Hein, R; Schmidt, CM; Sirokay, JD; Toma, M | 1 |
| Ayati, N; Beheshti, M; Hitzl, W; Hoellwerth, M; Jamshidi-Araghi, Z; Koelblinger, P; Pirich, C; Schweighofer-Zwink, G | 1 |
| Chen, J; Fan, L; Gai, Y; Hu, F; Lan, X; Li, M; Lin, Z; Ruan, W; Zhang, X; Zheng, H | 1 |
| Algarra, MA; Caminal, JM; Cortes-Romera, M; Del Carpio, LP; Gutierrez, C; Leiva, D; Lladò, L; Lorenzo, D; Piulats, JM; Ramos, E; Rodriguez-Vida, A; Rossi-Seoane, S; Ruiz, S; Sabaté-Llobera, A | 1 |
| Adileh, M; Asher, N; Ben-Betzalel, G; Ben-Yaacov, A; Grynberg, S; Lahat, G; Laks, S; Miodovnik, M; Mor, E; Nissan, A; Nizri, E; Schachter, J; Schtrechman, G; Shapira, R; Shimonovitz, M; Steinberg, Y; Stoff, R; Zippel, D | 1 |
| Chen, Y; Wu, Y; Zeng, Q; Zhang, F; Zhang, X; Zhou, J | 1 |
| Chen, KC; Chiu, YJ; Chu, PY; Li, CY; Wang, TH | 1 |
| Hijikata, Y; Hosono, M; Kanagaki, M; Takahashi, M; Umehana, M | 1 |
| Balermpas, P; Beintner-Skawran, S; Dimitriou, F; Freiberger, SN; Gstrein, NA; Holzmann, D; Huellner, MW; Kenkel, D; Looman, EL; Maurer, A; Mauthe, T; Meerwein, CM; Messerli, M; Mueller, SA; Rupp, NJ; Sartoretti, T; Schaab, JA; Soyka, MB | 1 |
| Burger, H; Holness, J; Twycross, SH | 1 |
| Kim, SJ; Lee, JW; Nam, SB | 1 |
| Been, LB; Damude, S; Deckers, EA; Hoekstra, HJ; Kruijff, S; Muller Kobold, AC; van Ginkel, RJ; van Leeuwen, BL; Vrielink, OM; Wevers, KP | 1 |
| Aarntzen, EHJG; Gerritsen, WR; van Willigen, WW | 1 |
| Albano, D; Alongi, P; Familiari, D; Fornito, MC; Galia, M; Ganduscio, G; Grassedonio, E; Laudicella, R; Messina, M; Midiri, M; Ruggeri, A; Scalisi, S; Spada, M | 1 |
| Hicks, RJ; Iravani, A; Sandhu, S | 1 |
| Aimn Working Group, Y; Annunziata, S; Caobelli, F; Laudicella, R; Pizzuto, DA | 1 |
| Baldari, S; Baratto, L; Iagaru, A; Laudicella, R; Minutoli, F | 1 |
| Castello, A; Lopci, E | 1 |
| Bhargava, P; Flynt, L; Marcal, L | 1 |
| Graham, M; Priya, S | 1 |
| Abe, Y; Fujii, R; Igaki, H; Imahori, Y; Itami, J; Kurihara, H; Morita, T; Nakamura, M; Nakamura, S; Nakayama, Y; Nishioka, S; Okamoto, H | 1 |
| Cheng, Z; Liu, W; Yao, Y; Zuo, Z | 1 |
| Annovazzi, A; Carpano, S; Cognetti, F; Ferraresi, V; Giannarelli, D; Pasqualoni, R; Sciuto, R; Vari, S | 1 |
| Altun, GD; Taş, A; Taştekin, E; Üstün, F | 1 |
| Forschner, A; Garbe, C; Gückel, B; la Fougère, C; Martus, P; Nikolaou, K; Olthof, SC; Pfannenberg, C; Vach, W | 1 |
| Arpacı, E; Olguner, AA; Orhan, E; Şahin, E; Yılmaz, H | 1 |
| Ammari, S; Antonios, L; Dercle, L; Deutsch, E; Gómez, RGH; Marabelle, A; Moya-Plana, A; Robert, C; Saenger, Y; Schwartz, LH; Seban, RD; Yeh, R | 1 |
| Bodet-Milin, C; Dréno, B; Eugène, T; Khammari, A; Mesnard, C; Nguyen, JM | 1 |
| Clements, W; Haydon, A; Mar, V; McLean, C; Moore, M; Nguyen, J; Shackleton, M; Yap, KS | 1 |
| Basler, L; Bogowicz, M; Dummer, R; Förster, R; Gabryś, HS; Guckenberger, M; Hogan, SA; Huellner, MW; Kudura, K; Levesque, MP; Pavic, M; Tanadini-Lang, S; Vuong, D | 1 |
| Bundschuh, RA; Dittrich, D; Essler, M; Lütje, S; Pyka, T; Scheidhauer, K | 1 |
| Aparici, CM; Davidzon, G; Franc, BL; Iagaru, A; Moradi, F; Nakamoto, R; Nguyen, J; Nobashi, TW; Reddy, SA; Rosenberg, J; Zaba, LC | 1 |
| Hindié, E | 1 |
| Akhurst, T; Au-Yeung, G; Galligan, A; Hicks, RJ; Hofman, MS; Hunter, MO; Iravani, A; Kee, D; Lasocki, A; Lau, PKH; Osman, MM; Sandhu, S; Wallace, R; Weppler, AM | 1 |
| Baynosa, J; Cheng, D; De Guzman, MD; Doyle, GM; Jones, MS; Kirgan, D; McNicoll, CF; Rivera, MR; St Hill, CR | 1 |
| Aberle, S; Callahan, J; Fullerton, S; Herschtal, A; Hicks, RJ; Iravani, A; Keyaerts, M; Mangana, J; McArthur, GA; Milne, D; Neyns, B; Wong, A | 1 |
| Ch'ng, S; Chakera, AH; Emmett, L; Fung, S; Gonzalez, M; Holtkamp, LHJ; Lee, K; Nieweg, OE; Saw, RPM; Stretch, JR; Thompson, JF | 1 |
| Annovazzi, A; Annunziata, S; Bergomi, S; Pasqualoni, R; Sciuto, R | 1 |
| Schrage, YM; Stahlie, EHA; Stokkel, MPM; van Akkooi, ACJ; van der Hiel, B; van Houdt, WJ; Wouters, MW | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Calabretta, R; Hacker, M; Haug, A; Hoeller, C; Karanikas, G; Li, X; Mitterhauser, M; Pichler, V | 1 |
| Huang, L; Liu, Y; Meng, F; Ran, P | 1 |
| Abraham, V; Samarasam, I; Surendran, S; Zechariah, P | 1 |
| Lyburn, ID; Nawwar, AA; Searle, J | 1 |
| Álamo-de-la-Gala, MDC; Calvo-Morón, MC; García-Gómez, FJ; León-Asuero-Moreno, I; Ríos-Martín, JJ | 1 |
| Boellaard, M; Boellaard, R; Brouwers, AH; de Heer, EC; Jalving, M; van Sluis, J | 1 |
| Barat, M; Barret, M; Cottereau, AS; Dohan, A; Gaujoux, S; Guegan-Bart, S; Guillo, E; Hoeffel, C; Soyer, P | 1 |
| Baffour, FI; Bartlett, DJ; Broski, SM; Erie, AJ; Glazebrook, KN | 1 |
| Jaimini, A; Jain, A; Jain, M; John, AR; Kishore, B; Pandit, AG; Sharma, A; Singh, A; Vishnoi, MG | 1 |
| Dieng, M; Einstein, AJ; Emmett, L; Khanna, N; Lord, SJ; Menzies, AM; Morton, RL; Nguyen, M; Nieweg, OE; Nijhuis, AAG; Saw, RPM; Thompson, JF; Turner, RM; Zeng, J | 1 |
| Bodet, D; García-Patos, V; González-Cruz, C; Muñoz-Couselo, E | 1 |
| Ding, J; Ding, L; Li, N; Meng, X; Sheng, X; Wang, F; Wang, S; Yang, Z; Yao, S; Zhang, Y; Zhu, H | 1 |
| Barber, TW; Cameron, R; Haydon, A; Mar, V; Nguyen, J | 1 |
| Su, M; Wang, D; Xiao, J | 1 |
| Martineau, P; Moghimi, S; Wilson, D | 1 |
| Ahmed, N; Binns, C; Ilyas, MW; Muzaffar, S; Usmani, S | 1 |
| Avner, M; Caplan, N; Cohen, JE; Lotem, M; Orevi, M; Popovtzer, A | 1 |
| Brodland, DG; Taylor, NA | 1 |
| Deandreis, D; Dummer, R; Grünig, H; Huellner, MW; Husmann, L; Kudura, K; Liberini, V; Mangana, J; Maurer, A; Messerli, M; Mihic-Probst, D; Orita, E; Pizzuto, DA; Rupp, N; Skawran, S | 1 |
| Creytens, D; Kruse, V; Ost, P; Spaas, M; Van den Broeck, B | 1 |
| Giuliano, P; Ulaner, GA | 1 |
| Czech, N; Forschner, A; Franzius, C; Garbe, C; Gutzmer, R; Matiszick, A; Meier, F; Sachse, MM; Schüssler, F; Völker, C; Wagner, G | 1 |
| Awada, G; Everaert, H; Keyaerts, M; Neyns, B; Vermeulen, S | 1 |
| Dieng, M; Einstein, AJ; Lord, SJ; Morton, RL; Nieweg, OE; Nijhuis, AAG; Saw, RPM; Thompson, JF; Turner, RM | 1 |
| Chen, C; Hu, X; Huang, Q; Jiang, M; Tang, Y | 1 |
| Fahy, AS; Jakub, JW; MacArthur, TA | 1 |
| Been, LB; Brabander, T; Grünhagen, DJ; Lemstra, C; Mooyaart, AL; Mulder, EEAP; Stahlie, EHA; van Akkooi, ACJ; van der Veldt, AAM; Vegt, E; Verburg, FA; Verhoef, C; Verver, D | 1 |
| De Spiegeleer, B; Juanito, G; Lawal, I; Maes, A; Sathekge, M; Van de Wiele, C; Vander, BK | 1 |
| Ghezzi, CL; Schneider Galvão, G; Schuch, A; Torres, L | 1 |
| Datinger, C; Dunzinger, A; Lengauer, RA; Loidl, A; Mehraban, N; Pichler, R; Walcherberger, B | 1 |
| Daisaki, H; Ishibashi, M; Ito, K; Kanekura, T; Kitajima, K; Nakajo, M; Soeda, F; Tanemura, A; Watabe, T; Yamazaki, N | 1 |
| Arslan, E; Beyhan, E; Çermik, TF; Ergül, N; Erol Fenercioğlu, Ö | 1 |
| Baa, AK; Rastogi, S; Sachani, H; Shamim, SA; Tripathy, S | 1 |
| Contreras, C; Knopp, MV; Miller, ED; Wright, CL | 1 |
| Afshar-Oromieh, A; Alberts, I; Fischlin, C; Mingels, C; Rominger, A; Wartenberg, J | 1 |
| Eigentler, TK; Forschner, A; Garbe, C; Gückel, B; Keim, U; la Fougère, C; Martus, P; Nikolaou, K; Olthof, SC; Pfannenberg, C; Vach, W | 1 |
| Hicks, RJ; Hofman, MS; McArthur, GA; Wong, ANM | 1 |
| Kannan, R; Madden, K; Pavlick, A; Raad, RA | 1 |
| Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S | 1 |
| Bargiggia, S; Dainese, E; Parente, F | 1 |
| Beiderwellen, K; Deuschl, C; Forsting, M; Grüneisen, J; Herrmann, K; Heusch, P; Kirchner, J; Lauenstein, TC; Sawicki, LM; Umutlu, L | 1 |
| Brennan, I; Johnston, C; Murphy, J | 1 |
| Forschner, A; Garbe, C; Gückel, B; la Fougère, C; Nikolaou, K; Pfannenberg, C; Schmidt, H; Schwenzer, N; Seith, F | 1 |
| Arnous, MMR; Hu, F; Lan, X; Qin, C | 1 |
| Arsenault, F; Plouznikoff, N | 1 |
| Choy, I; Saw, RPM; Thompson, JF; Young, CJ; Zahid, A | 1 |
| Valente, MA | 1 |
| Anconina, R; Ezroh Kazap, D; Hod, N; Lantsberg, S; Levin, D | 1 |
| Connolly, M; Crowther, S; Feeney, J; Gillis, A; Kelleher, F; McKenna, MC; Molloy, K | 1 |
| Ga, A; Kakkar, N; Kaushal, V; Mittal, BR; Parihar, AS; Seam, RK; Sood, A; Sood, K | 1 |
| Anwar, H; Dimitrakopoulou-Strauss, A; Haberkorn, U; Hassel, JC; Kopp-Schneider, A; Larribere, L; Sachpekidis, C; Winkler, J | 1 |
| Courbon, F; Dercle, L; Meyer, N; Pascal, P; Weyts, K | 1 |
| Alharbi, AA; Aljared, A; Huellner, MW | 1 |
| Cheng, Z; Kuang, D; Song, S; Zhu, X; Zou, S | 1 |
| Chua, M; Donahoe, S; Estall, V; Gyorki, D; Henderson, M; Herschtal, A; Hicks, RJ; Kee, D; Lewin, J; McArthur, GA; McCormack, CJ; Pohl, M; Pope, K; Sandhu, S; Sanelli, A; Sayers, L; Shackleton, M; Speakman, D; Spillane, J; Te Marvelde, L; Walpole, I | 1 |
| Asioli, S; Dalpiaz, G; Fanti, S; Marchiori, E; Rea, G | 1 |
| Fang, Y; Liu, T; Ma, PQ; Sun, C; Xu, LB; Xu, SF; Yu, SJ; Zhang, WJ; Zhang, XX; Zhao, ZG | 1 |
| Anwar, H; Dimitrakopoulou-Strauss, A; Haberkorn, U; Hassel, JC; Kopp-Schneider, A; Larribere, L; Sachpekidis, C; Winkler, JK | 1 |
| Antoch, G; Grueneisen, J; Heusch, P; Klode, J; Pöppel, TD; Schaarschmidt, BM; Schadendorf, D; Stebner, V; Stoffels, I; Umutlu, L | 1 |
| Dika, E; Diodato, S; Fanti, S; Gardini, A; Lambertini, M; Patrizi, A; Ravaioli, GM; Veronesi, G; Zannetti, G | 1 |
| Been, LB; Faut, M; Hoekstra, HJ; Kruijff, S; van Ginkel, RJ; van Leeuwen, BL | 1 |
| McBean, R; Peng, L | 1 |
| Ambrosini, V; Ardizzoni, A; Comito, F; Melotti, B; Sperandi, F | 1 |
| Carlino, MS; Emmett, L; Guminski, AD; Kapoor, R; Liu, V; Lo, S; Long, GV; Menzies, AM; Tan, AC | 1 |
| Mittra, E; Nobashi, T | 1 |
| Bermejo, J; Fornons-Servent, R; Marcoval, J; Sabaté-Llobera, A | 1 |
| Liu, Y | 1 |
| Dehghani, L; Kramkimel, N; Larger, E; Lebtahi, R; Mallone, R; Mikail, N; Soyer, P | 1 |
| Dimitrakopoulou-Strauss, A; Hassel, JC; Kopp-Schneider, A; Larribère, L; Sachpekidis, C | 1 |
| Humm, JL; Ito, K; Ni, A; Schöder, H; Teng, R; Weber, WA; Wolchok, JD | 1 |
| Cassou-Mounat, T; Huchet, V; Jehanno, N; Luporsi, M | 1 |
| Lu, Y | 1 |
| Akbulut, A; Ayan, A; Deveci, G; Koca, G | 1 |
| Alavi, A; Baruch, E; Boursi, B; Eshet, Y; Gholami, S; Houshmand, S; Mamtani, R; Margalit, O; Markel, G; Mitchell, TC; Shacham-Shmueli, E; Werner, TJ; Yang, YX | 1 |
| Dimitrakopoulou-Strauss, A; Hakim-Meibodi, L; Hassel, JC; Kopp-Schneider, A; Sachpekidis, C | 1 |
| Buset, CS; Dummer, R; Mangana, J | 1 |
| Glitza Oliva, IC; Safa, H | 1 |
| Harada, K; Irisawa, R; Kanzaki, A; Kiriyama, N; Maeda, T; Tsuboi, R | 1 |
| Bates, BM; Beck, S; Bell, AH; Bowtell, DD; Browning, J; Byrne, DJ; Choong, DY; Desai, J; Etemadmoghadam, D; Fellowes, AP; Fox, SB; Iravani, A; Khoo, C; McEvoy, CR; Mileshkin, L; Nastevski, V; Prall, OW; San Leong, H; Smith, K; Tothill, RW; Xu, H | 1 |
| Álamo-de la Gala, MC; de la Cinta Calvo-Morón, M; de la Cruz-Merino, L; de la Riva-Pérez, PA; García-Gómez, FJ | 1 |
| Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A | 1 |
| Dick, J; Dimitrakopoulou-Strauss, A; Enk, AH; Hassel, JC; Lang, N; Sachpekidis, C; Schulz, C; Slynko, A | 1 |
| Albright, RC; Manohar, S | 1 |
| Grangeon-Chapon, C; Lacour, JP; Montaudié, H; Picard, A; Razzouk-Cadet, M | 1 |
| Abgral, R; Alavi, Z; Amrane, K; Delcroix, O; Gouva, S; Keromnes, N; Le Goupil, D; Quere, G; Querellou, S; Salaun, PY; Schick, U | 1 |
| Ammari, S; Barker, L; Bigorgne, AE; Dercle, L; Deutsch, E; Finkel, G; Gartrell, RD; Marabelle, A; Mokrane, FZ; Moya-Plana, A; Nemer, JS; Robert, C; Saenger, Y; Schwartz, LH; Seban, RD; Yeh, R | 1 |
| Javadi, MS; Rowe, SP; Solnes, LB; Tulbah, RI | 1 |
| Glatz, K; Itin, P; Ivanova, K; Nicolas, G; Zippelius, A | 1 |
| Blank, CU; Haanen, JB; Stokkel, MP; van der Hiel, B | 1 |
| Ichimura, K; Kaji, M; Matsuo, T; Ogino, Y; Tanaka, T | 1 |
| Bredgaard, R; Lock-Andersen, J; Matzen, SH | 1 |
| Berlangieri, SU; Lee, ST; Scott, AM; Tan, GJ | 1 |
| Bastiaannet, E; Bonenkamp, JJ; Hoekstra, HJ; Hoekstra, OS; Koelemij, R; Niebling, MG | 1 |
| Bagrosky, BM; Gonzalez, R; Klingensmith, WC; Koo, PJ; Lewis, KD | 1 |
| Cho, A; Kwon, HJ; Lee, CS; Lee, K; Lee, SC; Yi, JH | 1 |
| Blasi, MA; Calcagni, ML; Giordano, A; Indovina, L; Mattoli, MV; Mulè, A; Petrone, G; Rufini, V; Sammarco, MG | 1 |
| Formstecher, P; Guerreschi, P; Huglo, D; Kluza, J; Marchetti, P; Martinot-Duquennoy, V; Mortier, L; Qassemyar, A; Ravasi, L; Scalbert, C | 1 |
| de Bruyn, M; de Jong, JR; Dierckx, RA; Elsinga, PH; Helfrich, W; Ramakrishnan, NK; Rybczynska, AA; van Waarde, A | 1 |
| Bikhchandani, J; Richards, AT; Smith, RB; Wood, J | 1 |
| Altenbernd, J; Bockisch, A; Klode, J; Nagarajah, J; Rosenbaum-Krumme, S; Tekin, G; Wieder, HA | 1 |
| Bourgeois, AC; Bradley, YC; Chang, TT; Fish, LM | 1 |
| Adams-Huet, B; Anderson, J; Lazaga, FJ; Mathews, D; Oz, OK | 1 |
| Cambron, S; Seltzer, M; Shelton, T; Siegel, A | 1 |
| Kim, EK; Park, JH; Park, WJ | 1 |
| Kung, HF; Ploessl, K; Zhu, L | 1 |
| Baulieu, F; Benbouzid, F; Cachin, F; Cammilleri, S; Chezal, JM; D'Incan, M; Degoul, F; Gachon, F; Gaudy, C; Gillet, B; Granel-Brocard, F; Grange, JD; Isnardi, V; Kelly, A; Labeille, B; Lacour, JP; Merlin, C; Mestas, D; Meyer, N; Miot-Noirault, E; Payoux, P; Razzouk-Cadet, M; Tychyj, C | 1 |
| Barron, B; Eaton, BR; Fox, T; Galt, JR; Kim, HS; Kim, S; Landry, J; Liu, Y; Schreibmann, E; Schuster, DM | 1 |
| Bar-Sela, G; Eran, A; Kaidar-Person, O | 1 |
| Anne, PR; Bar-Ad, V; Dicker, A; Doyle, L; Eldredge-Hindy, H; Eschelman, D; Gonsalves, C; Intenzo, C; Li, J; Ohri, N; Sato, T | 1 |
| Bodell, MA; Kraus, ES; Lipson, EJ; Sharfman, WH | 1 |
| Alabbas, H; Meguerditchian, AN; Ramjaun, A; Rodriguez Rivera, AM | 1 |
| Alavi, A; Goncalves, MD; Torigian, DA | 1 |
| Campbell, A; McCarthy, M; McIvor, J; Siew, T | 1 |
| Aigner, RM; Feichtinger, M; Gstettner, C; Klein, A; Pau, M; Reinbacher, KE; Wallner, J; Zemann, W | 1 |
| Hussey, D; Metser, U; Murphy, G | 1 |
| Bowyer, SE; Hicks, RJ; Long, GV; Lyle, M; McArthur, GA; Millward, M; Raleigh, JM; Rao, AD; Sandhu, S | 1 |
| Kyle, S; Law, WP | 1 |
| Li, ZG; Qin, XJ | 1 |
| Abel, F; Haalck, T; Klutmann, S; Schumacher, U; Yanar, M | 1 |
| Alavi, A; Algazy, KM; Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Heitjan, DF; Hu, J; Kaiser, J; O'Dwyer, PJ; Panosian, JT; Pontiggia, L; Rangwala, R; Redlinger, M; Schuchter, LM; Tan, KS; Torigian, DA; Troxel, AB; Vaughn, DJ | 1 |
| Fukui, T; Kawaguchi, K; Nishimura, M; Taniguchi, T; Yokoi, K | 1 |
| Cohen, VM; Grantham, M; Islam, S; Papastefanou, VP; Sagoo, MS; Szyszko, T | 1 |
| Dai, D; Gu, H; Song, X; Wang, J; Xu, W; Zhu, L | 1 |
| Friedman, KP; Kannan, R; Pavlick, A; Raad, RA | 1 |
| Dimitrakopoulou-Strauss, A; Haberkorn, U; Hassel, JC; Larribere, L; Pan, L; Sachpekidis, C | 1 |
| Bottino, D; DeMario, M; Geho, D; Goss, GD; Hansen, AR; Jarutat, T; Jonker, DJ; Karanikas, V; Lassen, UN; Mau-Sorensen, M; Meulendijks, D; Roessler, M; Schellens, JH; Schostack, KJ; Simcox, ME; Siu, LL; Vega-Harring, SM; Wang, K; Zhong, H | 1 |
| Bagaria, SP; Etzioni, D; Gray, RJ; Haddad, D; Pockaj, BA; Wasif, N | 1 |
| Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM | 1 |
| Chen, TY; Hsiao, SY | 1 |
| Doss, M; Edwards, KW; Hayes, SB; Huang, M; Walia, R; Yu, JQ | 1 |
| Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Hodi, FS; Kim, K; O'Day, S; Van den Abbeele, AD; Weber, J; Yap, JT; Zukotynski, K | 1 |
| Fotos, JS; Sogge, SM; Tulchinsky, M | 1 |
| Emri, G; Erdei, I; Fedinecz, N; Galuska, L; Gellén, E; Janka, E; Juhász, I; Lukács, R; Péter, Z; Remenyik, É; Sántha, O | 1 |
| Adachi, S; Koizumi, M; Kojo, M; Kubota, K; Matsuno, S; Morioka, N; Nishimura, M; Nishioka, S; Seto, H; Yamamoto, H | 1 |
| Rohren, EM | 1 |
| Avramova-Cholakova, S; Garcheva, M; Ivanova, S; Petrova, E; Vassileva, J | 1 |
| Chin-Lenn, L; McKinnon, JG; Teman, CJ; Urbanellis, P | 1 |
| Bosenberg, MW; Held, MA; Long, GV; Marzuka-Alcala, A; Meeth, KM; Micevic, G; Scolyer, RA; Stern, DF; Theodosakis, N | 1 |
| Ahmed, S; Lowder, L; Mahoney, B; McDonald, N | 1 |
| Eigentler, T; Pfannenberg, C; Schüle, SC | 1 |
| Bailey, ND; Hodi, FS; Keraliya, A; Nishino, M; Ott, PA; Ramaiya, NH; Tirumani, SH | 1 |
| Alabed, YZ; Sakellis, C | 1 |
| Bacanovic, S; Burger, IA; Hafner, J; Huellner, MW; Stolzmann, P | 1 |
| Marcus, C; Perng, P; Subramaniam, RM | 1 |
| Aide, N; Binns, D; Bourhis, D; Callahan, J; Desmonts, C; Hicks, RJ; Hofman, MS; Le Roux, PY; Quak, E; Robin, P; Salaun, PY | 1 |
| Altini, C; Ferrari, C; Merenda, N; Niccoli Asabella, A; Rubini, D; Rubini, G | 1 |
| Aghayev, A; Alabed, YZ; Sakellis, C; Van den Abbeele, AD | 1 |
| Boisserie, F; Brown, MP; Cebon, J; Desai, J; Dienstmann, R; Evers, S; Lassen, U; Lestini, B; Meresse, V; Schostack, K; Su, F; Tabernero, J; Zhang, W | 1 |
| Cho, A; Keum, KC; Lee, CS; Lee, JH; Lee, SC; Suh, YG | 2 |
| Eigentler, TK; Garbe, C; la Fougère, C; Nikolaou, K; Pfannenberg, C; Schüle, SC | 1 |
| Amaria, RN; Bagrosky, BM; Glueck, DH; Gonzalez, R; Koo, PJ; Kreidler, SM; Kwak, JJ; Lewis, K; Schmitt, RJ | 1 |
| Joshua, AM; Langer, DL; Metser, U; Singnurkar, A; Wang, J | 1 |
| Broski, SM; Glazebrook, KN; Moran, EK; Nathan, MA | 1 |
| Bach, AM; Carollo, G; Mannelli, L; Nougaret, S; Ragucci, M | 1 |
| Dimitrakopoulou-Strauss, A; Hassel, JC; Sachpekidis, C | 1 |
| Álvarez-Pérez, RM; Borrego-Dorado, I; Caballero-Gullón, L; Martínez-Esteve, A; Sancho-Márquez, MP | 1 |
| Shiau, YC; Tsai, SY; Wang, SY; Wu, YW | 1 |
| Kaya, A | 1 |
| Barina, AR; Bashir, MR; Hanks, BA; Howard, BA; Jaffe, TA; Salama, AK | 1 |
| Bier, G; Eigentler, T; Garbe, C; Hoffmann, V; Kloth, C; Klumpp, B; La Fougère, C; Nikolaou, K; Othman, AE; Pfannenberg, C | 1 |
| Ahn, BC; Jeong, SY; Kang, SM; Lee, J; Lee, SJ; Lee, SW; Son, SH | 1 |
| Carlino, MS; Guminski, A; Kefford, RF; Kong, BY; Liniker, E; Long, GV; Menzies, AM; Ramanujam, S; Saunders, CA | 1 |
| Mena, E; Mirpour, S; Sheikhbahaei, S; Subramaniam, RM; Taghipour, M; Xiao, J | 1 |
| Braun, M; Falch, C; Kirschniak, A; Klumpp, B; Koenigsrainer, A; Mueller, S | 1 |
| Conrad, F; Freesmeyer, M; Goetze, S; Kaatz, M; Winkens, T | 1 |
| Giordano, S; Kemppainen, J; Koskivuo, I; Minn, H; Seppänen, M; Veräjänkorva, E; Vihinen, P | 1 |
| Gautam, S; Rathi, PM; Sharma, S | 1 |
| Boulahdour, H; Drouet, C; Morel, O | 1 |
| Banzo, I; García-Castaño, A; Jiménez-Bonilla, J; Martínez-Rodríguez, I; Quirce, R | 1 |
| Ganti, R; Peng, F; Wachsmann, JW | 1 |
| Avery, RJ; Covington, MF; Curiel, CN; Kuo, PH; Lattimore, L | 1 |
| Bärwolf, R; Freesmeyer, M; Zirnsak, M | 1 |
| Boshomane, T; Lawal, I; Lengana, T; Modiselle, M; Ololade, K; Reyneke, F; Sathekge, M; Vorster, M | 1 |
| Cangini, D; Chiarion-Sileni, V; Framarini, M; Galassi, R; Marzullo, A; Moretti, A; Passardi, A; Ridolfi, L; Ridolfi, R; Serra, L; Tauceri, F | 1 |
| Nguyen, BD; Pockaj, BA; Roarke, MC | 1 |
| Ahmadzadehfar, H; Biersack, HJ; Brockmann, H; Ezziddin, S; Schmiedel, A | 1 |
| Roarke, MC | 1 |
| Chung, DK; Ho Shon, IA; Saw, RP; Thompson, JF | 1 |
| Ahmadzadehfar, H; Biersack, HJ; Ezziddin, S; Palmedo, H; Reinhardt, M; Singh, B; Strunk, H; Tüting, T | 1 |
| Geller, MD; Gerard, PS; Mattern, M | 1 |
| Basset-Seguin, N; Filmont, JE; Groheux, D; Hindié, E; Kerob, D; Lebbé, C; Moretti, JL; Sarandi, F; Teyton, P; Toubert, ME | 1 |
| Baurain, JF; Crott, R; Krug, B; Lonneux, M; Pirson, AS; Vander Borght, T | 1 |
| Kawabe, T; Mineura, K; Miyamoto, J; Owada, K; Sasajima, H; Tatsuzawa, K | 1 |
| Brenot-Rossi, I; Chuto, G; Gaudy-Marqueste, C; Grob, JJ; Nicol, I; Richard, MA | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Dahmen, G; Jablonka, R; Kuehl, H; Rosenbaum, S; Veit-Haibach, P; Vogt, FM | 1 |
| Erickson, LA; Farley, DR; Flotte, TJ; Jakub, JW; Kottschade, LA; Markovic, SN; McWilliams, RR; Olivier, KR; Pittelkow, MR; Pulido, JS; Quevedo, JF; Schild, SE; Sekulic, A; Stoian, I; Tran, NV; Vile, RG; Vuk-Pavlovic, S; Weenig, RH; Wiseman, GA | 1 |
| Gershman, BM; Guo, H; Miao, Y; Shenoy, N; Sklar, LA; Yang, J | 1 |
| Chan, JL; Chen, S; Goydos, JS; Kempf, J; Le, MN; Lee, JH; Mehnert, JA; Shih, WJ; Yip, D; Yudd, A | 1 |
| Bode, B; Dummer, R; Fischer, DR; Goldinger, S; Imhof, L; Steinert, HC; Strobel, K; Veit-Haibach, P; von Schulthess, GK | 1 |
| Slaby, J; Suri, U | 1 |
| Bastiaannet, E; Hoekstra, HJ; Kobold, AC; Kruijff, S; Suurmeijer, AJ; van Ginkel, RJ | 1 |
| Bastiaannet, E; Brouwers, AH; de Klerk, JM; Hoekstra, HJ; Hoekstra, OS; Koelemij, R; Meijer, S; Oyen, WJ; van der Jagt, EJ; Wobbes, T | 1 |
| Carreras-Delgado, JL; Delgado-Bolton, RC; Fernández-Pérez, C; Gambhir, SS; Jiménez-Requena, F; Pérez-Vázquez, JM; Schwimmer, J | 1 |
| Desjardins, L; Levy-Gabriel, C; Lumbroso-le Rouic, L; Malhaire, C; Mariani, P; Petras, S; Piperno-Neumann, S; Plancher, C; Salmon, RJ; Servois, V | 1 |
| Balbi, T; Biasco, G; Castellucci, P; Di Cicilia, R; Fanti, S; Nannini, M; Pantaleo, MA; Zannetti, G | 1 |
| Eckstein, HH; Essler, M; Gee, MW; Gurdan, M; Maier, A; Mariss, J; Pelisek, J; Reeps, C; Wall, W | 1 |
| Avisar, E; Goodwin, WJ; Moffat, FL; Molina, MA; Serafini, AN; Sfakianakis, GN | 1 |
| Alavi, A; Bertagna, F; Biasiotto, G; Giubbini, R; Rodella, C; Werner, T | 1 |
| Antoch, G; Bockisch, A; Eberhardt, W; Esser, S; Forsting, M; Gölitz, P; Hamami, M; Heusner, T | 1 |
| Hatmaker, AR; Holt, GE; Kelley, MC; Mansour, AA; Schwartz, HS | 1 |
| Auerbach, M; Burgess, BL; McCannel, TA; Reddy, S | 1 |
| Baurain, JF; Beguin, C; Crott, R; Krug, B; Lonneux, M; Pirson, AS; Roch, I; Vander Borght, T | 1 |
| Al-Ibraheem, A; Buck, A; Schwaiger, M; Souvatzoglou, M | 1 |
| Kishimoto, S; Kubota, T; Matsushima, S; Nishida, K; Nishimura, T; Oda, M; Okuyama, C; Takenaka, H | 1 |
| Cicin, I; Ozpaçac, T; Ozülker, F; Ozülker, T | 1 |
| Bonnichon-Py, A; Foehrenbach, H; Le Floch, H; Mairovitz, A; Margery, J; Marotel, C; Pons, F; Rivière, F; Salles, Y; Staub, E; Vaylet, F | 1 |
| Aide, N; Denoyer, D; Dorow, DS; Greguric, I; Hicks, RJ; Katsifis, A; Neels, OC; Roselt, P; Taylor, SR | 1 |
| Allen-Auerbach, MS; Benz, MR; Chmielowski, B; Czernin, J; Gomez-Navarro, J; McCarthy, T; Radu, C; Ribas, A; Seja, E; Williams, JL | 1 |
| Aukema, TS; Bonfrer, JM; Korse, CM; Kroon, BB; Nieweg, OE; Olmos, RA; Vogel, WV; Wouters, MW | 1 |
| Boeing, C; Dissemond, J; Grabbe, S; Hillen, U; Klode, J; Poeppel, T | 1 |
| Cherry, SR; Li, C; Mitchell, GS | 1 |
| Chin, KJ; Finger, PT | 1 |
| Aukema, TS; Klop, WM; Kroon, BB; Nieweg, OE; Valdés Olmos, RA; Vogel, WV; Wouters, MW | 1 |
| Horn, J; Lock-Andersen, J; Loft, A; Sjøstrand, H | 1 |
| Crott, R; Krug, B; Pirson, AS; Vander Borght, T | 1 |
| Abgral, R; Cavarec, MB; Couturier, O; Keromnes, N; Le Duc-Pennec, A; Le Roux, PY; Querellou, S; Salaun, PY; Sassolas, B | 1 |
| Buzaid, AC; Camargo, EE; Etchebehere, EC; Romanato, JS; Santos, AO | 1 |
| Haug, AR; Klingenstein, A; Nentwich, MM; Schaller, UC; Tiling, R | 1 |
| Hafner, J | 1 |
| Minn, H; Vihinen, P | 1 |
| Kim, J; Visioni, A | 1 |
| Bartenstein, P; Berking, C; Coppenrath, E; La Fougere, C; Melzer, HI; Pfluger, T; Schneider, V; Weiss, M | 1 |
| Gomaa, O; Kalkanis, A; Kalkanis, D; Paes, FM; Sfakianakis, GN | 1 |
| Ahn, BC; Hong, CM; Jeong, SY; Kang, S; Lee, HJ; Lee, J; Lee, SJ; Lee, SW; Song, BI | 1 |
| Bussmann, C; Cousin, M; Eberle, L; Huellner, MW; Linder, T; Soyka, JD; Strobel, K | 1 |
| Bastiaannet, E; Brouwers, AH; Hoekstra, HJ; Kobold, AC; Kruijff, S; Speijers, MJ | 1 |
| Fulham, M; Prakoso, E; Selby, WS; Thompson, JF | 1 |
| Bastiaannet, E; Hoekstra, HJ; Hoekstra, OS | 1 |
| Chevreau, C; Courbon, F; Julian, A; Meyer, N; Payoux, P; Wagner, T; Zerdoud, S | 1 |
| Aardalen, K; Aziz, N; Gambhir, SS; Hughes, NP; Kaplan, A; Stuart, D; Tseng, JR | 1 |
| Aractingi, S; Avril, MF; Boitier, F; Guégan, S; Kerob, D; Khosrotehrani, K; Mansard, S; Maubec, E; Merheb, C; Moguelet, P; Mortier, L; Nassar, D; Nguyen Huu, S; Oster, M; Prignon, A; Richard, MA | 1 |
| Buerke, B; Gerss, J; Heindel, W; Puesken, M; Weckesser, M; Wessling, J | 1 |
| Lindskog, DM; Nikkhou, K; Talusan, P | 1 |
| Davidson, J; Sundram, F | 1 |
| Mudun, A; Ozkan, G; Sanli, Y; Turkmen, C; Yegen, G | 1 |
| Borri, A; Brambilla, D; Casiraghi, M; Ciprandi, B; De Pas, T; Donghi, SM; Galetta, D; Gasparri, R; Guarize, J; Maisonneuve, P; Petrella, F; Solli, P; Spaggiari, L; Tessitore, A; Veronesi, G | 1 |
| Brennan, C; Campos, C; Graeber, TG; Heguy, A; Huse, JT; Kastenhuber, ER; Komisopoulou, E; Larson, SM; Linkov, I; Mellinghoff, IK; Osborne, JR; Palaskas, N; Phelps, ME; Plaisier, SB; Port, E; Rohle, D; Sander, C; Schultz, N; Taschereau, R; Tran, C; Wong, J; Wu, H; Yannuzzi, N | 1 |
| Fischer, DR; Haerle, SK; Holzmann, D; Huber, GF; Murer, K; Soyka, MB; Strobel, K | 1 |
| Gutzeit, A; Jacob, AL; Kos, S; Menter, T; Schubert, T; Takes, M | 1 |
| Querellou, S | 1 |
| Abbott, RA; Acland, KM; Harries, M; O'Doherty, M | 1 |
| Chung, D; Howman-Giles, R; Thompson, JF; Uren, RF | 1 |
| Bastiaannet, E; Brouwers, AH; Hoekstra, HJ; Hospers, GA; Kruijff, S; Nagengast, WB; Speijers, MJ; Suurmeijer, AJ | 1 |
| Golden, MJ; Hartshorne, MF; Katzman, J; Turk, ZA; Wheir, WH | 1 |
| Belloni, B; Essler, M; Haller, B; Hein, R; Krause, BJ; Link, A; Mirceva, V; Souvatzoglou, M; Thaler, M | 1 |
| Chevreau, C; Courbon, F; Meyer, N; Mourey, L; Wagner, T; Zerdoud, S | 1 |
| Collyer, JC; Ghazali, N; Tighe, J | 1 |
| Aarntzen, EH; Blokx, WA; Boerman, OC; Bonenkamp, JJ; de Vries, IJ; De Wilt, JH; Figdor, CG; Jacobs, JF; Lesterhuis, WJ; Mus, RD; Oyen, WJ; Punt, CJ; Srinivas, M; Troost, EG; van Rossum, MM; Windhorst, AD | 1 |
| Delaloye, AB; Denys, A; Leyvraz, S; Orcurto, V; Prior, JO; Schalenbourg, A; Schnyder, P; Voelter, V; Zografos, L | 1 |
| Eirini, L; Emmanouil, L; Hans-Günther, M; Liodaki, E; Liodakis, E; Machens, HG; Nikolaos, PA; Othonas, P; Papadopoulos, O; Papadopulos, NA | 1 |
| Bomalaski, JS; Evans, MJ; Jungbluth, AA; Ku, T; Larson, SM; Old, L; Ritter, G; Rosenfeld, E; Stelter, L; Zanzonico, P | 1 |
| Aboagye, EO; Alam, IS; Awais, RO; Brickute, D; Carroll, L; Nguyen, QD; Smith, G; Tomasi, G; Turton, DR; Twyman, FJ; Witney, TH | 1 |
| Bastiaannet, E; Brouwers, AH; Hoekstra, HJ; Hoekstra, OS; Oyen, W; Thompson, JF; Uyl-de Groot, CA; van der Jagt, EJ; van Ooijen, B; Verzijlbergen, F | 1 |
| Buck, A; Burger, C; Burger, IA; Huser, DM; von Schulthess, GK | 1 |
| Millward, MJ | 1 |
| Amaravadi, R; Callahan, J; Chapman, P; Flaherty, KT; Hicks, RJ; Kim, KB; Lee, RJ; McArthur, GA; Nolop, K; Puzanov, I; Ribas, A; Sosman, JA | 1 |
| Allan, C; Barbour, A; Bayley, G; Burmeister, B; Burmeister, E; Dwyer, P; Foote, M; Lambie, D; Meakin, J; Pullar, A; Smithers, M; Thomas, J | 1 |
| Kejariwal, D; Mansour, D | 1 |
| Barron, BJ; Dhanasekaran, R; Kim, HS; Lawson, DH; Piduru, SM; Schuster, DM | 1 |
| Ho, LT; Montion, R; Ngo, V; Vuu, H | 1 |
| Carvajal, RD; Lyall, A; Ulaner, G; Vargas, HA | 1 |
| Borbély, K; Fülöp, M; Kásler, M; Lengyel, Z; Remenár, E | 1 |
| Herold, CJ; Karanikas, G; Mayerhoefer, ME; Prosch, H; Weber, M | 1 |
| Abernethy, AP; Beasley, GM; Broadwater, G; Eikman, EA; Marzban, S; Parsons, C; Salama, AK; Selim, MA; Tyler, DS; Wong, T; Zager, JS | 1 |
| Coleman, RE; Lungren, MP; Welling, RD | 1 |
| Alslev, L; Engell-Noerregaard, L; Hendel, HW; Johannesen, HH; Svane, IM | 1 |
| Costouros, NG; Groome, T; Kashani-Sabet, M; Lee, GO; Leong, SP | 1 |
| Bastiaannet, E; Brouwers, AH; de Jong, JR; Hoekstra, HJ; Hoekstra, OS; Suurmeijer, AJ | 1 |
| Aerts, MA; De Looze, D; Mana, F; Neyns, B; Reenaers, C; Urbain, D | 1 |
| Han, KM; Lee, JH; Lee, WA; Park, SG | 1 |
| Carlino, MS; Haydu, LE; Kefford, RF; Lebowitz, PF; Long, GV; Martin Curtis, C; Menzies, AM; Saunders, CA | 1 |
| Brogsitter, C; Kämmerer, E; Kotzerke, J; Stein, A; Wunderlich, G; Zöphel, K | 1 |
| Baumert, BG; Kleijnen, J; Sauerland, S; Scheibler, FJ; Schröer-Günther, MA; Schürmann, C; Westwood, ME; Wolff, RF | 1 |
| McCannel, TA; Sai, V; Straatsma, BR; Wen, JC | 1 |
| Berthezene, Y; Bracoud, L; Durupt, F; Giammarile, F; Journe, C; Jouvet, JC; Morelec, I; Thomas, L; Thomson, V; Yanes, M | 1 |
| Kahr, HS; Lund, B; Mejlgaard, E | 1 |
| Balzarini, L; Chiti, A; Lopci, E; Monti, L | 1 |
| Bonardel, G; Chargari, C; Foehrenbach, H; Le Moulec, S; Védrine, L | 1 |
| Mojtahedi, A; Solomon, SB; Ulaner, GA | 1 |
| Bender, H; Biersack, HJ; Frohmann, JP; Grünwald, F; Kensy, J; Reinhardt, MJ; Reinhold, U; Willkomm, P | 1 |
| Abella-Columna, E; Valk, PE | 1 |
| Aigner, RM; Richtig, E; Schwarz, T | 1 |
| Lentz, SS | 1 |
| Belhocine, T; De Labrassinne, M; Lahaye, T; Pierard, G; Rigo, P | 1 |
| Borrego Dorado, I; Vázquez Albertino, R | 1 |
| Berner, U; Diehl, M; Döbert, N; Grünwald, F; Hamscho, N; Ludwig, R; Menzel, C | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L | 1 |
| Joyce, JM; Myers, DT; Petursson, SR; Pohland, ML | 1 |
| Dupont, P; Garmyn, M; Gysen, M; Hoe, LV; Mortelmans, L; Stas, M; Stroobants, S; Wever, ID | 1 |
| Cobben, DC; Elsinga, PH; Hoekstra, HJ; Jager, PL; Koopal, S; Tiebosch, AT; Wobbes, T | 1 |
| Frick, MP; Karabulut, N; Martin, DR; Yang, M | 1 |
| Carlson, KA; Davidson, D; Hutchins, GD; Jung, SH; Schauwecker, DS; Siddiqui, AR; Wagner, JD | 1 |
| Bueno, C; Carreras, JL; Lázaro, P; Longo, MI; Montz, R | 1 |
| Wagner, JD | 3 |
| Boisgard, R; Bouet, S; Frelat, G; Geffrotin, C; Horak, V; Le Chalony, C; Leplat, JJ; Tavitian, B; Tricaud, Y; Vincent-Naulleau, S | 1 |
| Brinkbäumer, K; Dresel, S; Grammerstorff, J; Hahn, K; Pfluger, T; Schmid, R; Schwenzer, K | 1 |
| Bourguet, P | 1 |
| Coleman, RE; Kitapci, MT | 1 |
| Franzius, Ch; Löffler, M; Nashan, D; Schober, O; Weckesser, M | 1 |
| Cobben, DC; Havenga, K; Hoekstra, HJ; Nienhuijs, S; Oyen, WJ; Ruers, TJ; Wobbes, T | 1 |
| Essner, R; Faries, MB; Glass, C; Gulec, SA; Kirgan, D; Lee, CC; Morton, DL | 1 |
| Carrasquillo, JA; Chen, CC; Little, RF; Nguyen, JD; Ryan, QC; Wilson, W | 1 |
| Larson, SM; Schöder, H; Yeung, HW | 1 |
| Diehl, M; Döbert, N; Grünwald, F; Hamscho, N; Menzel, C; Zaplatnikov, K | 1 |
| Boán, JF; Redondo, P | 1 |
| Grasee, EA; Wagner, JD | 1 |
| Coit, DG; Wong, SL | 1 |
| Carrasquillo, JA; Choyke, P; Finkelstein, SE; Galen, B; Hoffman, JM; Rosenberg, SA; Sherry, RM; White, DE | 1 |
| Alavi, A; Chiang, S; Fuster, D; Johnson, G; Schuchter, LM; Zhuang, H | 1 |
| Friedman, KP; Wahl, RL | 1 |
| Diehl, M; Döbert, N; Grünwald, F; Kranert, T; Manolopoulou, M; Menzel, C; Risse, J | 1 |
| Berchem, G; Decker, G; Lasar, Y; Pilloy, W; Snen, M | 1 |
| Schöder, H; Weng, LJ | 1 |
| Abidov, A; Berman, DS; D'agnolo, A; Hayes, SW; Waxman, AD | 1 |
| Fogarty, GB; Peters, LJ; Tartaglia, CJ | 1 |
| Bouhnik, JP; Even-Sapir, E; Lerman, H; Levin, C; Lievshitz, G; Miller, E; Yuzefovich, B; Zak, O | 1 |
| Bridji, B; Oudoux, A; Resche, I; Rousseau, C; Rousseau, T | 1 |
| Hoekstra, OS; Mijnhout, GS; Riphagen, II | 1 |
| Alavi, A; Bural, G; Kumar, R; Mavi, A | 1 |
| Francken, AB; Fulham, MJ; Hong, AM; McCarthy, WH; Millward, MJ; Thompson, JF | 1 |
| Alavi, A; Kumar, R | 1 |
| Mansberg, R; Mansberg, V; Nguyen, QH; Szeto, E | 1 |
| Altehoefer, C; Ghanem, N; Högerle, S; Kotter, E; Langer, M; Lohrmann, C; Nitzsche, E; Schäfer, O | 1 |
| Aamdal, S; Hersey, P; Joshua, A; Kefford, R; Lynch, K; Millward, MJ; Thomson, D; Toner, G | 1 |
| Fulham, MJ; Mohamed, A; Thambugala, GM | 1 |
| Nguyen, BD | 1 |
| Coleman, JJ; Daggy, J; Davidson, D; Hutchins, G; Logan, T; Love, C; Schauwecker, D; Wagner, JD; Wenck, S | 1 |
| Finger, PT; Kurli, M; Pavlick, AC; Reddy, S; Tena, LB | 2 |
| de Klerk, JM; Quarles van Ufford, HM; van Herk, G; van Waes, PF; Zoon, PJ | 1 |
| Bissé, E; Brink, I; Engelhardt, R; Epting, T; Yamada, K | 1 |
| Brink, I; Engelhardt, R; Yamada, K | 1 |
| Bhatnagar, P; Bybel, B; Singh, AD | 1 |
| Alavi, A; Aydin, A; Yu, JQ; Zhuang, H | 1 |
| Mackie, GC; Pohlen, JM | 1 |
| Gormley, TS; Ho, VB; Schraml, FV; Yudt, WM | 1 |
| Finger, PT; Kurli, M; Reddy, S; Tena, LB | 1 |
| Bonenkamp, JJ; Bulten, J; Hendrickx, BW; Oyen, WJ; van Herpen, CM | 1 |
| Hoksch, B; Jüngling, F; Körner, M; Schmid, RA; Weber, T | 1 |
| Franc, BL; Johnson, D; Leong, SP; Mari, C | 1 |
| Poon, A; Saunder, TH; Yap, KK | 1 |
| Bastiaannet, E; Hoekstra, HJ; Hoekstra, OS; Jager, PL; Meijer, S; Oyen, WJ; Wobbes, T | 1 |
| Avram, AM; Brown, RK; Francis, IR | 1 |
| Alavi, A; Bhutain, C; Chamroonrat, W; El-Haddad, G; Houseni, M; Mavi, A; Zhuang, H | 1 |
| Müller, SP | 1 |
| Akhurst, T; Brady, MS; Gonen, M; Hilton, S; Larson, S; Patel, A; Spanknebel, K | 1 |
| Bieber, T; Biersack, HJ; Bucerius, J; Huber, A; Jaeger, U; Joe, AY; Matthies, A; Reinhardt, MJ; Roedel, R; Strunk, H; Tüting, T | 1 |
| Chan, V; Chaudhry, AA; Clark, CT; Daw, HA; Kundranda, MN | 1 |
| Abe, S; Ikeda, M; Ishigaki, T; Kato, K; Kobayashi, H; Kubota, T; Nakano, S; Nishino, M; Tadokoro, M | 1 |
| Bautz, W; Fiedler, E; Greess, H; Hornegger, J; Hothorn, T; Kuwert, T; Nömayr, A; Pfahlberg, A; Platsch, G; Römer, W; Schuler, G; Schuler-Thurner, B | 1 |
| Clark, PB; Kraas, J; Levine, EA; Shen, P; Soo, V | 1 |
| Balan, K; Seshadri, N; Wat, J | 1 |
| Bawa, M; Galt, JR; Halkar, RK; Schuster, DM; Sidhu, G | 1 |
| Francken, AB; Fulham, MJ; Millward, MJ; Thompson, JF | 1 |
| Alavi, A; Newberg, A; Srinivas, SM; Sydow, BD | 1 |
| Bastiaannet, E; Hoekstra, HJ; Hoekstra, OS; Jager, PL; Oyen, WJ; Wobbes, T | 1 |
| Erasmus, JJ; Gershenwald, JE; Macapinlac, H; Pawlik, TM; Ross, MI; Truong, MT | 1 |
| Chin, K; Finger, PT; Iacob, CE | 1 |
| Akamoto, S; Maeta, H; Okano, K; Sugiyama, T; Usuki, H; Wakabayashi, H; Yachida, S | 1 |
| Benes, P; Koranda, P; Stárek, I | 1 |
| Miranda, EP | 1 |
| Hill, AD; Ryan, ER; Skehan, SJ | 1 |
| Chivers, SF; Nguyen, BD | 1 |
| Jacobs, M; Mantil, J; Rehani, B; Strohmeyer, P | 1 |
| Alvarez Pérez, RM; Borrego Dorado, I; López Martín, J; Vázquez Albertino, R | 1 |
| Coronado Poggio, M; Couto Caro, RM; Frutos Esteban, L; Lillo García, ME; Marín Ferrer, MD; Martín Curto, LM | 1 |
| Nieweg, O; Valdés Olmos, R | 1 |
| Gulec, SA | 1 |
| Aschoff, P; Bares, R; Brechtel, K; Claussen, CD; Eigentler, TK; Eschmann, SM; Garbe, C; Pfannenberg, C; Plathow, C; Schanz, S; Schlemmer, HP; Vonthein, R | 1 |
| Chatziioannou, AF; Chow, PL; De, A; Deroose, CM; Gambhir, SS; Loening, AM; Ray, P | 1 |
| Blumstein, NM; Buck, AK; Glatting, G; Mottaghy, FM; Neumaier, B; Ozdemir, C; Reske, SN; Scharffetter-Kochanek, K; Schubert, R; Sunderkötter, C; Wohlfart, P | 1 |
| Bautz, W; Hornegger, J; Hothorn, T; Kuwert, T; Nömayr, A; Römer, W; Wolz, G | 1 |
| Heffernan, EJ; Skehan, SJ | 1 |
| Dummer, R; Hany, TF; Skalsky, J; Steinert, HC; Strobel, K | 1 |
| Coakley, FV; Falk, MS; Franc, B; Hawkins, RA; Kashani-Sabet, M; Truitt, AK | 1 |
| Arens, AI; Beets-Tan, RG; Ramtahalsing, R; Teule, GJ; van den Ende, PL; Vliegen, RF | 1 |
| Cho, T; Formby, M; Lee, D; Wood, B | 1 |
| Baumann, K; Dummer, R; Joller-Jemelka, H; Kalff, V; Seifert, B; Skalsky, J; Steinert, HC; Strobel, K | 1 |
| Alavi, A; Basu, S | 1 |
| Aupérin, A; Avril, MF; Boitier, F; Cavalcanti, A; Kolb, F; Leboulleux, S; Lumbroso, J; Mamelle, G; Masson, F; Maubec, E; Spatz, A; Suciu, V | 1 |
| Koskivuo, IO; Minn, HR; Seppänen, MP; Suominen, EA | 1 |
| de Llano, SR; Mahmood, S | 1 |
| Dummer, R; Hany, TF; Husarik, DB; Pérez Lago, M; Steinert, HC; Strobel, K | 1 |
| Chin, K; Finger, PT; Kurli, M; Reddy, S; Tena, LB | 1 |
| Niederkohr, RD; Quon, A; Rosenberg, J; Shabo, G | 1 |
| Bhure, U; Dummer, R; Hany, TF; Joller-Jemelka, H; Kalff, V; Pérez Lago, M; Seifert, B; Skalsky, J; Steinert, HC; Strobel, K | 1 |
| Chiou, JF; Hsu, CH; Lin, SE; Tai, CJ; Wu, CH | 1 |
| Reinhardt, MJ | 1 |
| Acland, K; Constantinidou, A; Harries, M; Healy, C; Hofman, MS; O'Doherty, M | 1 |
| Bender, H; Biersack, HJ; Pleiss, C; Risse, JH | 1 |
| Chung, HJ; Chung, KY; Jung, JY; Roh, MR | 1 |
| Hall, NC; Martin, EW; Povoski, SP; Walker, MJ | 1 |
| Buckley, AF; Eisele, DW; Glastonbury, CM; Hawkins, RA; Lee, TJ | 1 |
| Chin, K; Finger, PT; Kurli, M | 1 |
| Beyer, T; Bockisch, A; Fitzek, M; Knoess, C; Kracht, L; Kühl, H; Maderwald, S; Pietrzyk, U; Vollmar, S; Wienhard, K | 1 |
| Doss, M; Haas, N; Milestone, BN; Parsons, RB; Yu, JQ | 1 |
| Benamor, M; Moulin-Romsee, G; Neuenschwander, S | 1 |
| Conzett, KB; Dummer, R; Kalff, V; Lago, MP; Schad, K; Seifert, B; Soyka, JD; Steinert, HC; Strobel, K; Veit-Haibach, P | 1 |
| Cameron, JD; Donaldson, MJ; Faia, LJ; Gunduz, K; Mullan, B; Pulido, JS; Salomão, DR | 1 |
| Carrasquillo, JA; Larson, SM | 1 |
| Blessing, C; Carl, M; Feine, U; Fierlbeck, G; Geiger, L; Rassner, G | 1 |
| Argenyi, EE; Dogan, AS; Hichwa, RD; Ponto, LL; Urdaneta, LF; Watkins, GL | 1 |
| Glaspy, JA; Hawkins, RA; Hoh, CK; Lee, SJ; Maddahi, J; Phelps, ME; Weil, JA; Yao, WJ | 1 |
| Berthold, T; Böni, R; Buck, A; Burg, G; Huch Böni, RA; Marincek, B; Steinert, HC; von Schulthess, GK | 1 |
| Francis, IR; Gritters, LS; Wahl, RL; Zasadny, KR | 1 |
| Larcos, G; Maisey, MN | 1 |
| Wagner, HN | 1 |
| Böni, R; Burg, G; Huch-Böni, RA; Steinert, H; von Schulthess, GK | 1 |
| Berthold, T; Buck, A; Engel, H; Huch Böni, RA; Steinert, H; von Schulthess, GK | 1 |
| Clavo, AC; Wahl, RL | 1 |
| Hawkins, RA; Hoh, CK; Huang, SC; Phelps, ME; Wu, HM; Yao, WJ | 1 |
| Damian, DL; Fulham, MJ; Thompson, E; Thompson, JF | 1 |
| Ali, A; Alibazoglu, H; Fordham, E; LaMonica, G; Patel, PM | 1 |
| Brancato, R; Fazio, F; Freschi, M; Landoni, C; Lucignani, G; Modorati, G; Trabucchi, G | 1 |
| Coleman, JJ; Hutchins, G; Schauwecker, D; Wagner, JD | 1 |
| Böni, R; Capaul, R; Huch-Böni, RA; Steinert, H; von Schulthess, GK; Westera, G | 1 |
| Hustinx, R; Paquet, P; Piérard, GE; Rigo, P | 1 |
| Baum, RP; Hör, G; Kaufmann, R; Rinne, D | 1 |
| Johnson, T; Macfarlane, DJ; Sondak, V; Wahl, RL | 1 |
| Easton, EJ; Greene, FL; Holder, WD; White, RL; Zuger, JH | 1 |
| Carreras, JL; Gorospe, E; Maldonado, A; Montz, R; Nieto, C; Ortega, F; Pérez-Castejón, MJ; Ruiz, JA | 1 |
| Glass, EC; Gupta, RK; Hsueh, EC; Morton, DL; Qi, K; Yee, R | 1 |
| Blasberg, RG; Claffey, KP; Finn, R; Joshi, A; Joshi, R; Miyagawa, T; Oku, T; Sasajima, T; Tjuvajev, JG | 1 |
| Bicik, I; Buck, A; Huch, RA; Steinert, HC; Trachsel, C; Voellmy, DR; von Schulthess, GK | 1 |
| Eigtved, A | 1 |
| Ali, A; Alibazoglu, B; Alibazoglu, H; La Monica, G | 1 |
| Borgstein, PJ; Hoekstra, OS; Meijer, S; Mijnhout, GS; Pijpers, R; Teule, GJ | 1 |
| Dietlein, M; Groth, W; Krug, B; Lackner, K; Psaras, T; Scheidhauer, K; Schicha, H; Smolarz, K; Stützer, H | 1 |
| Delbeke, D | 1 |
| Coleman, JJ; Davidson, D; Hayes, JT; Hutchins, G; Love, C; Saxman, S; Schauwecker, D; Wagner, JD | 1 |
| Bicik, I; Engel, H; Krestin, GP; von Schulthess, GK; Wiesner, W | 1 |
| Collins, BT; Dunphy, FR; Lowe, VJ | 1 |
| Akhurst, T; Berlangieri, SU; Feigen, M; Hannah, A; McKay, WJ; Quong, G; Scott, AM; Zalcberg, J; Zimet, A | 1 |
| Andersson, AP; Dahlstrøm, K; Drzewiecki, KT; Eigtved, A; Friberg, L; Holm, S; Højgaard, L; Jensen, M; Rabøl, A; Sørensen, SS | 1 |
| Acland, KM; O'Doherty, MJ; Russell-Jones, R | 1 |
| Chisin, R; Freedman, N; Gimon, Z; Klein, M; Lotem, M; Marciano, R; Moshe, S | 1 |
| Brenner, W; Czech, N; Henze, E; Kampen, WU | 1 |
| Bar-Shalom, R; Blaufox, MD; Valdivia, AY | 1 |
| Coleman, E; Fisher, S; Hata, A; Keogan, M; Kherani, A; Nicholson, E; Onaitis, M; Seigler, HF; Tyler, DS | 1 |
| Czernin, J; Essner, R; Gambhir, SS; Jahan, SA; Park, K; Patel, A; Phelps, ME; Schwimmer, J; Shepherd, JE | 1 |
| Belli, F; Bombardieri, E; Cascinelli, N; Crippa, F; Gallino, F; Greco, M; Leutner, M; Pilotti, S | 1 |
| Dietlein, M; Gossmann, A; Groth, W; Krug, B; Lackner, K; Psaras, T; Scheidhauer, K; Schicha, H; Stützer, H | 1 |
| Ak, I; Pauwels, EK; Stokkel, MP | 1 |
| Daghighian, F; Essner, R; Glass, EC; Haigh, PI; Hsueh, EC; Huynh, Y | 1 |
| Burger, C; Dimitrakopoulou-Strauss, A; Strauss, LG | 1 |
| Graham, MM | 1 |
| Devillé, WL; Hoekstra, OS; Mijnhout, GS; Teule, GJ; van Tulder, MW | 1 |
| Acland, KM; Calonje, E; Healy, C; Higgins, E; Nunan, T; O'Doherty, M; Page, C; Russell-Jones, R | 1 |
| Hoegerle, S; Joe, A; Moser, E | 1 |
| Buck, A; Dankerl, A; Reske, SN; Schirrmeister, H | 1 |
| Fujibayashi, Y; Itoh, H; Kubota, T; Maruyama, I; Nishizawa, S; Tsuchida, T; Waki, A; Yamamoto, T; Yonekura, Y; Yoshida, M | 1 |
| Mandelkern, M; Tatlidil, R | 1 |
| Davidson, D; Hutchins, G; Jung, SH; Schauwecker, DS; Wagner, JD; Wenck, S | 1 |
| Biersack, HJ; Grünwald, F; Menzel, C; Risse, JH | 1 |
| Alavi, A; Fraker, DL; Mercier, GA | 1 |
| Blocklet, D; Donckier, V; Goldman, S; Laporte, M; Van Geertruyden, J; Vereecken, P | 1 |
| Chander, S; McCook, BM; Meltzer, CC | 1 |
| Cabrera Villegas, A; Gámez Cenzano, C; Martín Urreta, JC | 1 |
| Bomanji, JB; Costa, DC; Ell, PJ | 1 |
| Binns, DS; Greer, B; Hicks, RJ; Hogg, A; Kalff, V; Ware, RE | 1 |
| Askienazy, S; Bok, B; Grall, Y; Meignan, M; Misset, JL; Rain, JD; Talbot, JN | 1 |
| Nabi, HA; Zubeldia, JM | 1 |
| Hill, AD; O'Higgins, NJ; Prichard, RS; Skehan, SJ | 1 |
| Adèr, HJ; Boers, M; Comans, EF; De Gast, GC; Hoekstra, OS; Mijnhout, GS; Raijmakers, P; Teule, GJ | 1 |
| Aigner, RM; Nicoletti, R; Schwarz, T; Wolf, G | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L; Várady, E | 1 |
| Bégány, A; Esik, O; Galuska, L; Gilde, K; Hunyadi, J; Ocsai, H; Szakáll, S; Török, L; Trón, L | 1 |
| Algan, O; Hanson, JM; Kinsella, TJ; Levin, AB; Levine, RL; Mehta, MP; Mendoza, M; Nickles, RJ; Rozental, JM; Schrader, DA | 1 |
| Aaltonen, J; Brownell, AL; Karonen, SL; Korpela, H; Lindgren, J; Lindroth, L; Nikkinen, P | 1 |
| Brancato, R; Colombo, F; Fazio, F; Gilardi, MC; Lucignani, G; Modorati, G | 1 |
52 review(s) available for fluorodeoxyglucose f18 and Melanoma
| Article | Year |
|---|---|
GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives.
Topics: Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Publications; Skin Neoplasms | 2021 |
PET/CT variants and pitfalls in malignant melanoma.
Topics: COVID-19; Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; SARS-CoV-2; Skin Neoplasms | 2022 |
CT and PET/CT findings of primary pulmonary malignant melanoma: a case report and literature review.
Topics: Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed | 2023 |
Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2019 |
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2020 |
Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2020 |
Malignant Cutaneous Melanoma: Updates in PET Imaging.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Melanoma, Cutaneous Malignant; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2020 |
The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Topics: Animals; Antineoplastic Agents, Immunological; Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2021 |
Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiopharmaceuticals; Skin Neoplasms | 2021 |
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Molecular Targeted Therapy; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2017 |
Acute toxoplasmosis mimicking melanoma metastases: review of conditions causing false-positive results on (18)F-FDG PET/CT.
Topics: Antibodies, Protozoan; Diagnosis, Differential; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Immunoglobulin G; Immunoglobulin M; Lymphadenitis; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Skin Neoplasms; Tomography, X-Ray Computed; Toxoplasmosis | 2012 |
Positron emission tomography/computed tomography in melanoma.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Radionuclide Imaging; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2013 |
Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms | 2014 |
Non-cutaneous melanoma: is there a role for (18)F-FDG PET-CT?
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
PET/Computed Tomography and Patient Outcomes in Melanoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Outcome Assessment; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2015 |
(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Topics: Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2015 |
Imaging in cutaneous melanoma.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Positron-Emission Tomography; Sensitivity and Specificity; Skin Neoplasms | 2008 |
Metastatic malignant melanoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Immunotherapy; Magnetic Resonance Imaging; Melanoma; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Skin Neoplasms; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Incidence; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms | 2010 |
Positron emission tomography for benign and malignant disease.
Topics: Breast Neoplasms; Colorectal Neoplasms; Dermatitis, Contact; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2011 |
PET scanning in plastic and reconstructive surgery.
Topics: Breast Neoplasms; Diabetic Foot; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Keloid; Male; Melanoma; Multimodal Imaging; Neoplasm Staging; Plastic Surgery Procedures; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma; Surgical Flaps; Tomography, X-Ray Computed | 2012 |
F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Skin Neoplasms; Tomography, X-Ray Computed | 2012 |
Positron emission tomography imaging in melanoma and lymphoma.
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
[A proposal for the rational use of the PET in oncology].
Topics: Brain Neoplasms; Colorectal Neoplasms; Consensus; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Practice Guidelines as Topic; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Spain; Tomography, Emission-Computed | 2002 |
[Cost-effective PET investigations in oncology].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed; United States | 2002 |
New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in skin and ocular melanoma].
Topics: Eye Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2003 |
PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
Topics: Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lymphoma; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Care Management; Radiopharmaceuticals; Subtraction Technique; Systems Integration; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
[Positron-emission tomography in oncology].
Topics: Colorectal Neoplasms; Evidence-Based Medicine; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Update on diagnostic imaging for melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Role of surgery in patients with stage IV melanoma.
Topics: Brain Neoplasms; Decision Making; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Melanoma; Neoplasm Staging; Palliative Care; Radiography; Radiopharmaceuticals; Risk Factors; Tomography, Emission-Computed | 2004 |
Clinical use of positron emission tomography in the management of cutaneous melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphatic Metastasis; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2004 |
Fluorodeoxyglucose-PET in the management of malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2005 |
Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2005 |
Malignant melanoma: PET/CT as a staging procedure.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging | 2006 |
Cutaneous melanoma.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2008 |
Nuclear oncology 1984.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Bleomycin; Brain Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glioma; Humans; Liver Neoplasms; Male; Melanoma; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Neoplasms; Tomography, Emission-Computed | 1984 |
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
Topics: Artifacts; Brain Neoplasms; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphoma; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[Diagnostic value of positron emission tomography (PET) in clinical oncology].
Topics: Brain Neoplasms; Breast Neoplasms; Diagnosis, Differential; Digestive System Neoplasms; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Urogenital Neoplasms | 2000 |
PET imaging in oncology.
Topics: Colonic Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; United States | 2000 |
A review of the literature for whole-body FDG PET in the management of patients with melanoma.
Topics: Confidence Intervals; Cost-Benefit Analysis; Decision Support Techniques; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Peer Review, Research; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Technology Assessment, Biomedical; Tomography, Emission-Computed; Whole-Body Irradiation | 2000 |
Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours.
Topics: Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Melanoma; Odds Ratio; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2001 |
[Positron emission tomography (PET) in clinical oncology. Part II].
Topics: Adult; Aged; Colorectal Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphoma; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Clinical role of positron emission tomography in oncology.
Topics: Colorectal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Clinical applications of (18)F-FDG in oncology.
Topics: Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
Positron emission tomography for staging and management of malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
[Cost-effective PET scans in oncology].
Topics: Breast Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; United States | 2002 |
40 trial(s) available for fluorodeoxyglucose f18 and Melanoma
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Impact of
Topics: Aged; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Metastasectomy; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Survival Analysis; Treatment Outcome | 2017 |
The role of interim
Topics: Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2018 |
Clinical significance of signs of autoimmune colitis in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Colitis; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2019 |
(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Topics: Aged; Benzamides; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Male; Melanins; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Vacuoles | 2014 |
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2015 |
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Treatment Outcome; Young Adult | 2016 |
Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms; Young Adult | 2016 |
Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Astrocytoma; Carcinoma, Adenoid Cystic; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Hemangioma, Cavernous, Central Nervous System; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Melanoma; Middle Aged; Neurilemmoma; Optic Nerve Neoplasms; Orbital Neoplasms; Orbital Pseudotumor; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2008 |
Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed | 2009 |
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.
Topics: Blotting, Western; Caspase 3; Enzyme Activation; Excitatory Amino Acid Antagonists; Extracellular Signal-Regulated MAP Kinases; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Ki-67 Antigen; Melanoma; Mutation; Neoplasm Staging; Oncogene Protein v-akt; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; ras Proteins; Receptors, Metabotropic Glutamate; Riluzole | 2009 |
Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Skin Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2010 |
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Cell Proliferation; CTLA-4 Antigen; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed; Tumor Burden | 2010 |
A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases".
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchoscopy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Registries; Retrospective Studies; Sarcoma; Survival Rate; Time Factors; Tomography, X-Ray Computed; Young Adult | 2011 |
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Uveal Neoplasms; Young Adult | 2012 |
Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Female; Fluorodeoxyglucose F18; Hospital Costs; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Multidetector Computed Tomography; Neoplasm Staging; Netherlands; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms | 2012 |
Repeatability of FDG quantification in tumor imaging: averaged SUVs are superior to SUVmax.
Topics: Biological Transport; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Observer Variation; Positron-Emission Tomography; Reproducibility of Results; Thoracic Neoplasms; Time Factors | 2012 |
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Australia; Biomarkers, Tumor; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Diagnosis; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Monitoring, Physiologic; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Statistics, Nonparametric; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib | 2012 |
Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2012 |
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Topics: Adult; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Male; Melanoma; Mutation; Oximes; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Survival Analysis; Treatment Outcome | 2013 |
[18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Feasibility Studies; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
Topics: Adult; Aged; Aged, 80 and over; Decision Making, Computer-Assisted; Double-Blind Method; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Patient Selection; Preoperative Care; Radiography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
Topics: Abdominal Neoplasms; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Coincidence imaging using 2 dual-head gamma-camera systems, with and without attenuation correction.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Gamma Cameras; Gastrointestinal Neoplasms; Humans; Image Enhancement; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Melanoma; Middle Aged; Ovarian Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Melanins; Melanoma; Middle Aged; Positron-Emission Tomography; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.
Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Amidines; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Indans; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole-Body Counting | 2005 |
Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Preoperative Care; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2006 |
Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Iofetamine; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Uveal Neoplasms | 2006 |
Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience.
Topics: Adult; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Pilot Projects; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2007 |
Positron emission tomography in the detection and management of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Tomography, Emission-Computed | 1996 |
Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.
Topics: Adult; Deoxyglucose; Feasibility Studies; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Pilot Projects; Prospective Studies; Tomography, Emission-Computed | 1997 |
Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Topics: Adult; Aged; Aged, 80 and over; False Negative Reactions; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Risk Factors; Sensitivity and Specificity; Tomography, Emission-Computed; Whole-Body Counting | 1998 |
Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
Topics: Adolescent; Adult; Bone Neoplasms; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed; Ultrasonography | 1999 |
Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Topics: Adult; Aged; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 1999 |
Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy.
Topics: Colonic Neoplasms; Fluorodeoxyglucose F18; Humans; Melanoma; Patient Selection; Tomography, Emission-Computed | 2001 |
Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Patient Care; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Statistics as Topic; Surveys and Questionnaires; Tomography, Emission-Computed; Whole-Body Counting | 2002 |
456 other study(ies) available for fluorodeoxyglucose f18 and Melanoma
| Article | Year |
|---|---|
Synchronous Recurrence of Metachronous Lung Cancer and Hodgkin Lymphoma Within an Axillary Lymph Node Isolated on 18F-FDG PET/CT.
Topics: Adult; Aged, 80 and over; Axilla; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lung; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Thorax | 2022 |
FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Retrospective Studies; Risk Assessment; Survival Analysis; Tumor Burden | 2021 |
Spontaneous Regression of a Middle Ear Melanoma.
Topics: Aged; Ear, Middle; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Melanoma; Oximes; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Tumor Burden | 2022 |
[A case of metastatic melanoma in the gallbladder].
Topics: Aged; Fluorodeoxyglucose F18; Gallbladder; Humans; Magnetic Resonance Imaging; Male; Melanoma; Skin Neoplasms | 2021 |
A fare case of pancreatic metastasis from malignant melanoma mimicking pancreatitis on
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Pancreatic Neoplasms; Pancreatitis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
Imaging PD-L1 Expression in Melanoma Brain Metastases.
Topics: B7-H1 Antigen; Brain Neoplasms; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2022 |
Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Tumor Burden | 2022 |
Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Immunotherapy; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
Unusual Diffuse Ground-Glass Opacities in the Lungs on 18F-FDG PET/CT: A Case of Melanoma With Pulmonary Metastasis.
Topics: Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography | 2022 |
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunotherapy; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms | 2022 |
[
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Melanoma; Melanoma, Cutaneous Malignant; Positron Emission Tomography Computed Tomography; Quinolines; Skin Neoplasms | 2022 |
"The Benefit Of Positron Emission Tomography/Computed Tomography In Stage I And Stage II Melanomas With High-Risk Decisiondx-Melanoma Scores".
Topics: Dichlorodiphenyl Dichloroethylene; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Testicular Neoplasms | 2022 |
18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinase Kinases; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Skin Neoplasms | 2022 |
Melanin-Targeted PET Imaging With 18F-PFPN for Identifying Gastric Metastatic Melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanins; Melanoma; Middle Aged; Neoplasms, Second Primary; Positron-Emission Tomography; Radiopharmaceuticals; Stomach | 2022 |
Diagnostic impact of
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2022 |
Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy.
Topics: Brain; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Melanoma, Cutaneous Malignant; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2022 |
The predictive power of FDG-PET imaging with regard to immunotherapy in real-life conditions in advanced melanoma: An exploratory study.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab.
Topics: Arthritis; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography | 2023 |
Comparison of 18F-FDG PET/CT and ultrasound in staging of patients with malignant melanoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Staging; Polyesters; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Suppuration | 2022 |
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Topics: Biopsy; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Seminal Vesicles | 2023 |
Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
Topics: Cohort Studies; Fluorodeoxyglucose F18; Humans; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2023 |
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Lymphatic Metastasis; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Tumor Burden | 2023 |
Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Internal Thoracic Vein Tumor Thrombus From Sternal Melanoma Metastasis on 18 F-FDG PET/CT.
Topics: Aged; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Sternum; Thrombosis | 2023 |
Malignant Melanoma of the External Auditory Canal on 68 Ga-FAPI PET/CT.
Topics: Ear Canal; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2023 |
Metastatic melanoma extending along the inferior vena cava to its branches and venous plexus: a rare route metastasis characterized by [
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Vena Cava, Inferior | 2023 |
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Kynurenine; Melanoma; Melanoma, Cutaneous Malignant; Prospective Studies; Tryptophan | 2023 |
Pitfalls in evaluating FDG-PET/CT results in melanoma patients - A case series.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography | 2023 |
Predictive value and accuracy of [
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Ipilimumab; Melanoma; Metabolic Diseases; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Melanin-targeted [
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanins; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Retrospective Studies | 2023 |
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Uveal Neoplasms | 2023 |
PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Diagnostic value of 18 F-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in acral melanoma-predominant Asian patients.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2023 |
Pembrolizumab-Associated Pneumonitis Resembling Lymphangitic Carcinomatosis in a Melanoma Patient.
Topics: Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Melanoma; Middle Aged; Pneumonia; Positron Emission Tomography Computed Tomography | 2023 |
Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging.
Topics: Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Melanoma; Paranasal Sinus Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies | 2023 |
The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Young Adult | 2019 |
S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; S100 Calcium Binding Protein beta Subunit | 2019 |
18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma.
Topics: Antibodies; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Sarcoidosis | 2019 |
Clinical and Prognostic Value of
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms | 2020 |
Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event.
Topics: Fat Necrosis; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Subcutaneous Fat | 2020 |
"Eye-Black" Sign Secondary to Nivolumab Immunotherapy.
Topics: Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography | 2020 |
Comparison of
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Boron Compounds; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Phenylalanine; Positron-Emission Tomography; Young Adult | 2020 |
A Rare Presentation of Melanoma as a Retroperitoneal Mass Seen on FDG PET.
Topics: Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retroperitoneal Neoplasms | 2020 |
Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors | 2020 |
The Clinical Significance of Incidental Parotid Uptake in a PET/CT Study: A Diagnostic Algorithm.
Topics: Adenolymphoma; Biopsy, Fine-Needle; Databases, Factual; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Melanoma; Parotid Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Risk Assessment; Skin Neoplasms | 2019 |
Influence of
Topics: Cohort Studies; Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
Efficacy of positron emission tomography and computed tomography in clinical staging of cutaneous malignant melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sentinel Lymph Node Biopsy | 2020 |
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Topics: CTLA-4 Antigen; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Melanoma; Positron Emission Tomography Computed Tomography; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies; Skin Neoplasms; Tumor Burden | 2020 |
Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
Metastatic melanoma presenting as intravenous tumour thrombus.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Thrombosis | 2020 |
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Topics: Adult; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Progression-Free Survival; Radiopharmaceuticals; Tumor Burden; Young Adult | 2020 |
Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; ROC Curve; Treatment Outcome; Tumor Burden; Vemurafenib | 2020 |
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2020 |
Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?
Topics: CTLA-4 Antigen; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Melanoma; Positron-Emission Tomography; Prognosis; Programmed Cell Death 1 Receptor; Skin Neoplasms | 2020 |
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Topics: Fluorodeoxyglucose F18; Humans; Immunity; Ipilimumab; Melanoma; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography; Retrospective Studies; Treatment Outcome | 2020 |
The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
Topics: Biopsy; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms | 2021 |
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Liver; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Spleen | 2020 |
Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2020 |
A Rare Case of Solitary Pituitary Metastasis From Spitzoid Melanoma Detected by FDG PET/CT.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Pituitary Neoplasms; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2020 |
The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries.
Topics: Aged; Aged, 80 and over; Aorta; Arteritis; CTLA-4 Antigen; Female; Fluorodeoxyglucose F18; Humans; Iliac Artery; Immune Checkpoint Inhibitors; Immunity, Innate; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Skin Neoplasms | 2020 |
FDG PET/CT Findings of Melanoma in a Renal Allograft.
Topics: Adult; Allografts; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Kidney Transplantation; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography | 2020 |
Primary malignant melanoma of the stomach: a rare entity.
Topics: Biopsy; Diagnosis, Differential; Dyspepsia; Dyspnea; Fatigue; Fluorodeoxyglucose F18; Gastrectomy; Gastroscopy; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Stomach Neoplasms; Treatment Outcome | 2020 |
Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
Topics: Antibodies, Monoclonal, Humanized; Colitis; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Thyroiditis | 2021 |
Thyroid Metastasis From Cutaneous Melanoma on an 18F-FDG PET/CT Study.
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Thyroid Neoplasms | 2020 |
Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Prospective Studies; Reproducibility of Results; Tomography, X-Ray Computed; Tumor Burden; Workflow | 2021 |
BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Mutation; Panniculitis; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2021 |
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence.
Topics: Conjunctival Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2020 |
Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
Topics: Australia; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2021 |
Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.
Topics: Adult; Back; Biopsy; Diagnosis, Differential; Disease Progression; Female; Fluorodeoxyglucose F18; Granuloma; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lymph Nodes; Lymphadenopathy; Mediastinum; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms | 2021 |
Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Isotope Labeling; Male; Melanoma; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Radiometry; Tissue Distribution; Translational Research, Biomedical; Urologic Neoplasms | 2021 |
Findings and Resolution of Melanoma Perineural Spread Along the Greater Auricular Nerve on FDG PET/CT and MRI.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Peripheral Nerves; Positron Emission Tomography Computed Tomography | 2021 |
Primary Malignant Melanoma of the Oropharynx Presented on 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Oropharynx; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
FDG PET Findings Post-COVID Vaccinations: Signs of the Times?
Topics: Aged; COVID-19 Vaccines; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron Emission Tomography Computed Tomography; Vaccination | 2021 |
COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT.
Topics: Aged, 80 and over; Biological Transport; COVID-19 Vaccines; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Melanoma; Positron Emission Tomography Computed Tomography; Vaccination | 2021 |
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma.
Topics: COVID-19; COVID-19 Vaccines; Fluorodeoxyglucose F18; Humans; Lymphadenopathy; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; SARS-CoV-2 | 2021 |
CT and PET-CT Surveillance in Stages 3A to 3D Melanoma Results in More False-Positive than True-Positive Findings and Should Not be Routinely Recommended.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography | 2021 |
Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2021 |
Spatiotemporal Evolution of Radiation Myositis on 18F-FDG PET/CT Following Hypofractionated Radiotherapy of Intramuscular Melanoma Metastases.
Topics: Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Myositis; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Radiation Dose Hypofractionation; Radiation Injuries | 2021 |
18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT.
Topics: Aged; Axilla; COVID-19 Vaccines; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Melanoma; Positron Emission Tomography Computed Tomography; Vaccination | 2021 |
PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT.
Topics: Delivery of Health Care; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Skin Neoplasms; Tomography, X-Ray Computed | 2021 |
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome.
Topics: Antibodies, Monoclonal, Humanized; Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tumor Burden | 2021 |
Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron Emission Tomography Computed Tomography | 2021 |
Difficulties encountered in the diagnosis of primary esophageal malignant melanoma by 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a case report.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2021 |
Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Biological Products; Combined Modality Therapy; Fluorodeoxyglucose F18; Herpesvirus 1, Human; Humans; Injections, Intralesional; Male; Melanoma; Middle Aged; Minnesota; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Ultrasonography | 2021 |
False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
Topics: Aged; Antineoplastic Agents, Immunological; Biological Products; Cohort Studies; False Positive Reactions; Female; Fluorodeoxyglucose F18; Herpesvirus 1, Human; Humans; Lymph Nodes; Male; Melanoma; Melanoma, Cutaneous Malignant; Oncolytic Virotherapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2021 |
Imaging findings of melanoma metastasis in the gallbladder.
Topics: Adult; Fluorodeoxyglucose F18; Gallbladder; Humans; Lymph Nodes; Male; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2022 |
Visceral Hepatic Leishmaniasis in a Melanoma Patient in FDG-PET.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Leishmaniasis, Visceral; Melanoma; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Topics: Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Melanoma; Positron Emission Tomography Computed Tomography; Prognosis; Treatment Outcome | 2022 |
18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT Findings of Bilateral Knee Osteoarthritis in a Patient With Uveal Malignant Melanoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Osteoarthritis, Knee; Positron Emission Tomography Computed Tomography; Quinolines | 2022 |
Malignant Melanoma of Glans Penis: Findings on 18F FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Penis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
FDG uptake in axillary lymph nodes after COVID-19 vaccination - a pitfall in a case of highly suspicious lymph node metastases of malignant melanoma.
Topics: Axilla; Breast Neoplasms; COVID-19; COVID-19 Vaccines; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; SARS-CoV-2; Vaccination | 2021 |
Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Melanoma; Middle Aged; Pneumonia; Positron Emission Tomography Computed Tomography | 2017 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autoantibodies; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Fluorodeoxyglucose F18; HLA-DR Antigens; Humans; Hypothyroidism; Immunoglobulins, Thyroid-Stimulating; Iodide Peroxidase; Iron-Binding Proteins; Killer Cells, Natural; Lung Neoplasms; Male; Melanoma; Middle Aged; Monocytes; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Thyroid Function Tests; Thyroiditis; Thyrotropin; Thyroxine; Triiodothyronine; Young Adult | 2017 |
Primary jejunal malignant melanoma detected by
Topics: Aged; Endoscopy, Gastrointestinal; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Jejunal Neoplasms; Melanoma; Positron Emission Tomography Computed Tomography | 2017 |
18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Melanoma; Middle Aged; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2017 |
Intra-articular Melanoma Metastasis in the Ankle Joint.
Topics: Aged; Ankle Joint; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography | 2017 |
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
Detection of Non-FDG-Avid Residual Sinonasal Malignant Melanoma in the Skull Base With 11C-Choline PET and Contrast-Enhanced MRI.
Topics: Carbon Radioisotopes; Choline; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Skull Base | 2017 |
Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lower Extremity; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; Skin Neoplasms; Thigh | 2017 |
Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients.
Topics: Australia; Colonoscopy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Prevalence; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Survival Rate | 2017 |
Endoscopic and histopathological analysis of incidental focal colorectal
Topics: Adenoma; Aged; Aged, 80 and over; Carcinoma; Colonoscopy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Precancerous Conditions; Radiopharmaceuticals; Retrospective Studies | 2018 |
Incidental Detection of Metastatic Malignant Melanoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT Imaging: Correlative Imaging With FDG PET/CT and Review of the Literature.
Topics: Aged, 80 and over; Biopsy, Fine-Needle; Edetic Acid; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Incidental Findings; Male; Melanoma; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Recurrence | 2018 |
Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Biopsy; Cicatrix; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Sarcoidosis; Skin | 2018 |
Incidental Detection of Synchronous Lung Melanoma on 18F-FDG PET/CT in a Patient With Parotid Gland Myoepithelial Carcinoma.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Melanoma; Middle Aged; Myoepithelioma; Parotid Neoplasms; Positron Emission Tomography Computed Tomography | 2018 |
Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.
Topics: Antineoplastic Agents; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Indoles; Melanoma; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Sulfonamides; Vemurafenib | 2018 |
BSREM Reconstruction for Improved Detection of In-Transit Metastases With Digital FDG-PET/CT in Patients With Malignant Melanoma.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms | 2018 |
Anal Malignant Melanoma Manifesting Hepatic Metastases Shown on FDG PET/CT.
Topics: Adult; Anus Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Melanoma; Neoplasm Recurrence, Local; Population Surveillance; Positron Emission Tomography Computed Tomography; Postoperative Period; Prognosis; Radiopharmaceuticals | 2018 |
Rapidly growing pulmonary ground-glass nodule caused by metastatic melanoma lacking uptake on 18F-FDG PET-CT.
Topics: Adult; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms | 2018 |
[The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Topics: Extremities; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Skin Neoplasms; Torso | 2018 |
Longitudinal studies of the
Topics: Antineoplastic Agents, Immunological; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Kinetics; Longitudinal Studies; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2018 |
Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Topics: Adult; Aged; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sentinel Lymph Node; Sentinel Lymph Node Biopsy | 2018 |
Considerations on 18FDG PET/CT and sentinel lymph node biopsy in AJCC stages I and II of melanoma.
Topics: Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2020 |
Pelvic lymph node dissection in metastatic melanoma to the groin should not be abandoned yet.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Groin; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2018 |
Innocent PET avidity in patient with metastatic melanoma.
Topics: Biological Transport; Diagnosis, Differential; Exercise; Fluorodeoxyglucose F18; Groin; Humans; Male; Melanoma; Middle Aged; Patient Education as Topic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms | 2018 |
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bone Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Middle Aged; Osteoblasts; Positron-Emission Tomography; Skin Neoplasms; Tomography, X-Ray Computed | 2018 |
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Prognosis; Programmed Cell Death 1 Receptor; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2018 |
PD-1 Blockade-induced Inflammatory Arthritis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Arthritis; Fluorodeoxyglucose F18; Humans; Joints; Male; Melanoma; Positron-Emission Tomography; Prednisolone; Programmed Cell Death 1 Receptor; Whole Body Imaging | 2018 |
Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lipoma; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2020 |
Focal mass-like cardiac uptake on oncologic FDG PET/CT: Real lesion or atypical pattern of physiologic uptake?
Topics: Adult; Aged; False Positive Reactions; Female; Fluorodeoxyglucose F18; Heart Diseases; Heart Neoplasms; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2019 |
Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Topics: Antineoplastic Agents, Immunological; Autoimmune Diseases; Biomarkers; Diffusion Magnetic Resonance Imaging; Exocrine Pancreatic Insufficiency; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lipase; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Nivolumab; Pancreatitis; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Radiopharmaceuticals | 2018 |
Can benign lymphoid tissue changes in
Topics: Antineoplastic Agents, Immunological; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Ipilimumab; Lymphoid Tissue; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2019 |
Prognostic value of baseline metabolic tumor volume measured on
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tumor Burden | 2019 |
Gallbladder Metastasis From Conjunctival Melanoma.
Topics: Conjunctival Neoplasms; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Risk Factors | 2019 |
FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biopsy; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron Emission Tomography Computed Tomography; Sarcoidosis | 2019 |
Primary Diffuse Leptomeningeal Melanomatosis of Spine: 18F-FDG PET Findings.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Meningeal Neoplasms; Positron Emission Tomography Computed Tomography; Spine | 2019 |
Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.
Topics: Antineoplastic Agents, Immunological; Colon; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunotherapy; Ipilimumab; Melanoma; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms | 2019 |
18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Longitudinal Studies; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Treatment Outcome; Vemurafenib | 2019 |
Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Melanoma; Nivolumab; Panniculitis; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2019 |
Cardiac Metastases in Melanoma.
Topics: Female; Fluorodeoxyglucose F18; Heart; Heart Neoplasms; Humans; Melanoma; Middle Aged; Positron-Emission Tomography; Skin Neoplasms | 2019 |
[
Topics: Antineoplastic Agents, Immunological; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Keratinocytes; Lung Neoplasms; Male; Melanoma; Middle Aged; Nivolumab; Positron Emission Tomography Computed Tomography; Prurigo; Radiopharmaceuticals; Skin Neoplasms | 2019 |
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
Topics: Aged; Alleles; Autoantigens; beta Catenin; Cyclin-Dependent Kinase Inhibitor p16; Extracellular Signal-Regulated MAP Kinases; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Melanoma; Neoplasm Metastasis; Oncogene Proteins, Fusion; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Skin Neoplasms | 2019 |
Pneumonitis Related to Melanoma Immunotherapy.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Immunotherapy; Male; Melanoma; Pneumonia; Positron Emission Tomography Computed Tomography; Quality of Life | 2019 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Nivolumab; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Survival Analysis; Thyroid Gland; Thyroiditis; Thyrotropin; Thyroxine; Triiodothyronine | 2019 |
Interstitial nephritis in immune checkpoint inhibitor therapy.
Topics: Aged; Female; Fluorodeoxyglucose F18; Glucocorticoids; Humans; Ipilimumab; Kidney; Melanoma; Nephritis, Interstitial; Positron Emission Tomography Computed Tomography; Skin Neoplasms; Treatment Outcome | 2019 |
Nivolumab-Induced Pneumonitis in Patient With Metastatic Melanoma Showing Complete Remission on 18F-FDG PET/CT.
Topics: Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Nivolumab; Pneumonia; Positron Emission Tomography Computed Tomography | 2019 |
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Protocols; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Staging; Nivolumab; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Skin Neoplasms; Tomography, X-Ray Computed | 2019 |
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunotherapy; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies; Transcriptome; Treatment Outcome; Young Adult | 2019 |
Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary.
Topics: Bone Diseases; Fluorodeoxyglucose F18; Humans; Lung Diseases; Lymphadenopathy; Male; Melanoma; Middle Aged; Neoplasms, Unknown Primary; Nivolumab; Positron Emission Tomography Computed Tomography; Sarcoidosis | 2019 |
Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
Topics: Aged; Antibodies, Monoclonal; Disease Progression; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Multimodal Imaging; Neoplasm Staging; Pituitary Diseases; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma.
Topics: Aged; Aged, 80 and over; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Uveal Neoplasms | 2014 |
[Franks wire-guided localization in excision of nonpalpable melanoma metastases].
Topics: Biopsy, Fine-Needle; Fluorodeoxyglucose F18; Humans; Melanoma; Multimodal Imaging; Palpation; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2013 |
Periarticular FDG Uptake on PET/CT in malignant melanoma-metastatic or misleading?
Topics: Aged; Diagnosis, Differential; Fluorodeoxyglucose F18; Gout; Humans; Joints; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2013 |
Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Skin Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2013 |
Anti-CTLA4 antibody therapy related complications on FDG PET/CT.
Topics: Antibodies, Monoclonal; CTLA-4 Antigen; Fluorodeoxyglucose F18; Humans; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
Regression of uveal melanoma after ru-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Female; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Male; Melanoma; Middle Aged; Prognosis; Radiopharmaceuticals; Retrospective Studies; Ruthenium Radioisotopes; Tomography, Emission-Computed, Single-Photon; Uveal Neoplasms | 2014 |
A prospective analysis of ¹⁸F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features.
Topics: Aged; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Uveal Neoplasms | 2013 |
Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Topics: Adult; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Indoles; Melanoma; Mice, SCID; Multimodal Imaging; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Skin Neoplasms; Sulfonamides; Time Factors; Tomography, X-Ray Computed; Tumor Burden; Vemurafenib; Xenograft Model Antitumor Assays | 2013 |
In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
Topics: Animals; Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Melanoma; Metabolic Clearance Rate; Mice; Mice, Nude; Organ Specificity; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, sigma; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Treatment Outcome | 2013 |
No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2014 |
18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Topics: Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Germany; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Factors; S100 Calcium Binding Protein beta Subunit; Sensitivity and Specificity; Skin Neoplasms; Survival Analysis; Survivors; Tomography, X-Ray Computed | 2013 |
Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Skin Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2013 |
Tracheal metastasis from melanoma detected with 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiography; Tomography, Emission-Computed; Tracheal Neoplasms | 2013 |
Extensive tuberculous lymphadenitis mimicking distant lymph node metastasis on F-18FDG PET/CT in a patient with a history of malignant melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Chemistry. Expanding the scope of fluorine tags for PET imaging.
Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluoxetine; Glucose; Halogenation; Humans; Melanoma; Neoplasms; Patient Selection; Plaque, Amyloid; Positron-Emission Tomography; Pyrazoles; Radiopharmaceuticals; Sulfonamides | 2013 |
Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Topics: Adult; Aged; Embolization, Therapeutic; Fluorodeoxyglucose F18; Glycolysis; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma; Middle Aged; Monte Carlo Method; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiation Dosage; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
Topics: Administration, Oral; Adult; Biopsy, Needle; Dermatologic Surgical Procedures; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Male; Melanoma; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2014 |
Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Melanoma; Microspheres; Middle Aged; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Uveal Neoplasms; Young Adult; Yttrium Radioisotopes | 2016 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Ipilimumab; Kidney Transplantation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mycophenolic Acid; Platinum Compounds; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Skin Neoplasms; Tacrolimus; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Muscle, Skeletal; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
FDG PET in early stage cutaneous malignant melanoma.
Topics: Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms | 2014 |
Minimal invasive biopsy of intraconal expansion by PET/CT/MRI image-guided navigation: a new method.
Topics: Adult; Aged; Carcinoma, Merkel Cell; Diplopia; Exophthalmos; Female; Fluorodeoxyglucose F18; Hamartoma; Humans; Image-Guided Biopsy; Imaging, Three-Dimensional; Lymphoma; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Minimally Invasive Surgical Procedures; Multimodal Imaging; Orbital Diseases; Orbital Neoplasms; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2014 |
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.
Topics: Aged; Antineoplastic Agents; Biopsy; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; MAP Kinase Signaling System; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Phosphorylation; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retrospective Studies; Signal Transduction; Skin Neoplasms; Treatment Outcome | 2014 |
Bilateral cryptorchidism mimicking external iliac lymphadenopathy in a patient with leg melanoma: role of FDG-PET and ultrasound in management.
Topics: Aged; Cryptorchidism; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lower Extremity; Lymph Node Excision; Lymph Nodes; Lymphatic Diseases; Male; Melanoma; Multimodal Imaging; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Ultrasonography | 2014 |
Primary anorectal melanoma on FDG PET/CT.
Topics: Aged; Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed | 2014 |
The microenvironment in the human lung partly determines the site of the first metastasis.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Microenvironment | 2014 |
Primary malignant melanoma of the thymus: report of a case.
Topics: Biopsy, Needle; Bone Neoplasms; Brachiocephalic Veins; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Pericardium; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Thymectomy; Thymus Neoplasms; Treatment Outcome | 2015 |
Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors.
Topics: Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 8; Eye Enucleation; Female; Fluorodeoxyglucose F18; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Monosomy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Uveal Neoplasms | 2014 |
[Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography/ computed tomography for N-and M-staging of malignant melanoma].
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2014 |
Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
Topics: Aged; Antibodies, Monoclonal; Fluorodeoxyglucose F18; Hepatitis; Humans; Ipilimumab; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Staging studies for cutaneous melanoma in the United States: a population-based analysis.
Topics: Aged; Aged, 80 and over; Cohort Studies; Cross-Sectional Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Magnetic Resonance Imaging; Male; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; SEER Program; Skin Neoplasms; Tissue Distribution; Tomography, X-Ray Computed; United States | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose F18; Humans; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Myelitis; Paraplegia; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
Uveal melanoma with diffuse bone marrow involvement.
Topics: Aged; Bone Marrow Neoplasms; Fatal Outcome; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Uveal Neoplasms | 2014 |
Solitary subcutaneous gouty nodule mimicking metastatic melanoma on FDG PET/CT.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Male; Medical Errors; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Subcutaneous Tissue; Tomography, X-Ray Computed | 2015 |
Bacillus Calmette-Guerin injections for melanoma immunotherapy: potential for a false-positive PET/CT.
Topics: Aged, 80 and over; BCG Vaccine; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Melanoma; Melanoma, Cutaneous Malignant; Multimodal Imaging; Radionuclide Imaging; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2015 |
Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed; Young Adult | 2015 |
Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphoma; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2015 |
Patient doses from PET-CT procedures.
Topics: Bulgaria; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiation Protection; Radiometry; Radiopharmaceuticals; Retrospective Studies; Software; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Kikuchi-Fujimoto lymphadenitis imitating metastatic melanoma on positron emission tomography: a case report.
Topics: Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Histiocytic Necrotizing Lymphadenitis; Humans; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2015 |
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.
Topics: Biological Transport; Cell Size; Drug Resistance, Neoplasm; Flow Cytometry; Fluorodeoxyglucose F18; Glucose; Hexokinase; Humans; Immunoblotting; Indoles; Melanoma; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; RNA Interference; Sulfonamides; Vemurafenib | 2015 |
Development of Malignant Melanoma of the Orbit in Previous Radiation Field.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasms, Radiation-Induced; Orbital Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
[Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma - disease progression or immunologically induced side effect?].
Topics: Aged; Antibodies, Monoclonal; Colon; CTLA-4 Antigen; Diagnosis, Differential; Disease Progression; Energy Metabolism; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Ipilimumab; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Multimodal Imaging; Neoplasm Staging; Nose Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Colitis; CTLA-4 Antigen; Drug-Related Side Effects and Adverse Reactions; Female; Fluorodeoxyglucose F18; Hepatitis; Humans; Ipilimumab; Lymphatic Diseases; Male; Melanoma; Middle Aged; Neoplasm Staging; Organ Specificity; Pancreatitis; Pneumonia; Positron-Emission Tomography; Thyroiditis; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Umbilical Plugoma Mimics Melanoma Metastasis on FDG PET/CT.
Topics: Aged, 80 and over; Diagnosis, Differential; Fluorodeoxyglucose F18; Hernia, Abdominal; Humans; Male; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Umbilicus | 2015 |
Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.
Topics: Adrenocortical Hyperfunction; Aged; Antibodies, Monoclonal; Antineoplastic Agents; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
[18F-FDG PET/CT in ocular and orbital abnormalities not only neopastic: comparison with traditional imaging].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Eye Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Orbital Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2015 |
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Topics: Antibodies, Monoclonal; Fluorodeoxyglucose F18; Humans; Immunotherapy; Ipilimumab; Male; Melanoma; Middle Aged; Multimodal Imaging; Pancreatitis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma.
Topics: Brachytherapy; Choroid; Choroid Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, Optical Coherence | 2015 |
Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
Topics: Adult; Aged; Decision Making; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Multimodal Imaging; Mutation; Neoplasm Metastasis; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Ontario; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Registries; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Imidazoles; Indoles; Male; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Oximes; Panniculitis; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed; Vemurafenib | 2016 |
Incidental Detection of Femoral Pseudoaneurysm at 18F-FDG PET/CT.
Topics: Aged; Aneurysm, False; Femoral Artery; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Remission Induction; Tomography, X-Ray Computed | 2016 |
Breast metastasis from melanoma mimicking inflammatory breast cancer.
Topics: Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Inflammatory Breast Neoplasms; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Conjunctival Melanoma on 18F-FDG PET/CT as a Second Primary Cancer.
Topics: Conjunctival Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasms, Second Primary; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma.
Topics: Choroid; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron-Emission Tomography | 2016 |
Reply.
Topics: Choroid; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron-Emission Tomography | 2016 |
Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.
Topics: Aged; Antibodies, Monoclonal; Colitis; Colon, Sigmoid; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Iopamidol; Ipilimumab; Male; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2016 |
Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multivariate Analysis; Positron Emission Tomography Computed Tomography; Probability; Recurrence; Retrospective Studies; ROC Curve; Skin Neoplasms; Tumor Burden | 2016 |
Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Survival Rate; Treatment Outcome | 2016 |
18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Topics: Adult; Aftercare; Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms | 2016 |
Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with 18F-FDG-PET/CT.
Topics: Aged; Anal Canal; Anus Neoplasms; Colon, Sigmoid; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Patient Selection; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Rectal Neoplasms; Rectum; Retrospective Studies; Treatment Outcome | 2016 |
Retrospective chart analysis of incidental findings detected by (18) F-fluorodeoxyglucose-PET/CT in patients with cutaneous malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Melanoma; Positron Emission Tomography Computed Tomography; Retrospective Studies; Skin Neoplasms | 2016 |
Primary Maligant Melanoma of the Oesophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Interferons; Liver Neoplasms; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT.
Topics: Adrenal Gland Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Melanoma; Middle Aged; Neoplasms, Unknown Primary; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib.
Topics: Adult; Antineoplastic Agents; Erythema Nodosum; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Melanoma; Oximes; Panniculitis; Positron Emission Tomography Computed Tomography; Pyridones; Pyrimidinones; Radiopharmaceuticals | 2017 |
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Colitis; Female; Fluorodeoxyglucose F18; Humans; Hypophysitis; Immunotherapy; Ipilimumab; Male; Melanoma; Middle Aged; Multimodal Imaging; Pancreatitis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies; Skin Neoplasms; Thyroiditis; Tomography, X-Ray Computed | 2017 |
FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec.
Topics: Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Oncolytic Virotherapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Breath-hold and free-breathing F-18-FDG-PET/CT in malignant melanoma-detection of additional tumoral foci and effects on quantitative parameters.
Topics: Adult; Aged; Aged, 80 and over; Breath Holding; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Respiration; Tomography, X-Ray Computed; Young Adult | 2017 |
Topics: Adult; Age Distribution; Asymptomatic Diseases; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Sex Distribution; Skin Neoplasms; South Africa | 2017 |
Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma.
Topics: Aged; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Infusion Pumps; Interferon-alpha; Lymphatic Diseases; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiography; Sentinel Lymph Node Biopsy; Splenomegaly; Withholding Treatment | 2008 |
Desmoplastic melanoma: true positive and false negative findings on F-18 FDG-PET/CT.
Topics: Aged, 80 and over; False Negative Reactions; Female; Fibroma, Desmoplastic; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2008 |
Splenic infarction mimicking a necrotizing metastasis of malignant melanoma on F-18 FDG PET/CT.
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Necrosis; Positron-Emission Tomography; Radiopharmaceuticals; Splenic Infarction; Splenic Neoplasms; Subtraction Technique; Tomography, X-Ray Computed | 2008 |
Benign F-18 FDG uptake along a mediastinoscopy tract: demonstration by F-18 FDG PET/CT imaging.
Topics: Female; Fluorodeoxyglucose F18; Humans; Mediastinoscopy; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed | 2008 |
Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, X-Ray Computed | 2008 |
Synchronicity.
Topics: Carcinoma, Papillary; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Squamous Cell; Positron-Emission Tomography; Radiography; Scalp; Skin Neoplasms; Thyroid Neoplasms | 2008 |
[Use of fluorine-18-FDG PET-CT scans in initial management and follow-up of patients with cutaneous melanoma].
Topics: Continuity of Patient Care; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2008 |
[Role of FDG PET-CT in cutaneous melanoma].
Topics: Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Neoplasms, Second Primary; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2008 |
Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.
Topics: alpha-MSH; Amino Acid Sequence; Animals; Binding, Competitive; Cell Line, Tumor; Feasibility Studies; Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Lactams; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Peptides, Cyclic; Reproducibility of Results; Staining and Labeling; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2009 |
Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nerve Growth Factors; Positron-Emission Tomography; Prognosis; Retrospective Studies; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tomography, X-Ray Computed; Uveal Neoplasms | 2009 |
Metastatic melanoma with multiple small bowel intussusceptions.
Topics: Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Intestine, Small; Intussusception; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2009 |
S-100B concentrations predict disease-free survival in stage III melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Immunoenzyme Techniques; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nerve Growth Factors; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tomography, X-Ray Computed; Young Adult | 2009 |
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Uveal Neoplasms | 2010 |
Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence.
Topics: Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Granular Cell Tumor; Humans; Melanoma; Middle Aged; Positron-Emission Tomography; Recurrence | 2009 |
Glucose metabolism in the vessel wall correlates with mechanical instability and inflammatory changes in a patient with a growing aneurysm of the abdominal aorta.
Topics: Aortic Aneurysm; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Imaging, Three-Dimensional; Male; Melanoma; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2009 |
Intra-operative use of PET probe for localization of FDG avid lesions.
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Melanoma; Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2009 |
Massive bilateral adrenal gland metastases from melanoma diagnosed by F18-FDG-PET/CT.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Aged; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2011 |
Association of positive dual-modality positron emission tomography/computed tomography imaging of primary choroidal melanoma with chromosome 3 loss and tumor size.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Choroid Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 3; Female; Fluorodeoxyglucose F18; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Topics: Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2010 |
Melanoma metastases to palatine tonsils obscured by physiological FDG uptake on PET/CT.
Topics: Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Palatine Tonsil; Positron-Emission Tomography; Tomography, X-Ray Computed; Tonsillar Neoplasms | 2010 |
FDG avid patchy bone marrow misinterpreted as melanoma metastases to bone in a case of aplastic anemia.
Topics: Aged; Anemia, Aplastic; Bone Marrow; Bone Neoplasms; Diagnosis, Differential; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Radionuclide Imaging; Radiopharmaceuticals | 2009 |
A case of malignant melanoma with cardiac and gallbladder metastases detected by FDG PET-CT.
Topics: Adult; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Heart Neoplasms; Humans; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Subtraction Technique; Tomography, X-Ray Computed | 2009 |
[Pulmonary malignant melanoma: primary or metastatic?].
Topics: Aged, 80 and over; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Positron-Emission Tomography; Skin Neoplasms; Tomography, X-Ray Computed | 2010 |
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.
Topics: Animals; Autoradiography; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Kidney; Melanins; Melanoma; Mice; Neoplasm Metastasis; Niacinamide; Positron-Emission Tomography; Pyridines; Substrate Specificity; Tomography, X-Ray Computed; Transplantation, Homologous; Whole Body Imaging | 2010 |
Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Nerve Growth Factors; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Sentinel Lymph Node Biopsy; Skin Neoplasms; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
Cerenkov luminescence tomography for small-animal imaging.
Topics: Animals; Cell Line, Tumor; Computer-Aided Design; Equipment Design; Equipment Failure Analysis; Fluorodeoxyglucose F18; Humans; Luminescent Measurements; Melanoma; Mice; Mice, Nude; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2010 |
[(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palladium; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden; Uveal Neoplasms | 2011 |
Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases.
Topics: Aged; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[PET scanning for malignant melanoma and positive sentinel node diagnostics].
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2010 |
The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Sensitivity and Specificity; Skin Neoplasms | 2010 |
Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lower Extremity; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed; Uveal Neoplasms | 2010 |
Sentinel lymph node excision and positron emission tomography and computed tomography in the initial stage of malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Skin Neoplasms; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
Melanoma imaging with highly specific PET probes: ready for prime time?
Topics: Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2011 |
PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiation Dosage; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
F-18 FDG PET positive hilar and mediastinal lymphadenopathy mimicking metastatic disease in a melanoma patient treated with interferon-alpha-2b.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Interferon-alpha; Lymphatic Diseases; Male; Mediastinal Diseases; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Melanoma of the middle ear: initial presentation, Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging and follow up.
Topics: Aged, 80 and over; Biopsy; Diagnosis, Differential; Ear Neoplasms; Ear, Middle; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neck Dissection; Neoplasm Staging; Parotid Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rare Diseases | 2011 |
The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nerve Growth Factors; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tomography, Spiral Computed | 2011 |
Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Capsule Endoscopy; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidence; Intestinal Neoplasms; Intestine, Small; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; New South Wales; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Skin Neoplasms; Survival Rate; Young Adult | 2011 |
Melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2011 |
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Topics: Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2011 |
Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.
Topics: Animals; Biomarkers, Tumor; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; Glucose; Humans; Imidazoles; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Melanoma; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins B-raf; Pyridines; Radionuclide Imaging; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Pregnancy promotes melanoma metastasis through enhanced lymphangiogenesis.
Topics: Animals; Cell Proliferation; Female; Fluorodeoxyglucose F18; Inflammation; Lymphangiogenesis; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Positron-Emission Tomography; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Animal; Skin | 2011 |
Usefulness of semi-automatic volumetry compared to established linear measurements in predicting lymph node metastases in MSCT.
Topics: Algorithms; Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Iohexol; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; ROC Curve; Software; Tomography, X-Ray Computed | 2011 |
False-positive positron emission tomography in patients with history of malignancy.
Topics: Adult; Anus Neoplasms; Biopsy; Breast Neoplasms; Carcinoma; Carcinoma, Lobular; Carcinoma, Squamous Cell; False Positive Reactions; Female; Fluorodeoxyglucose F18; Granular Cell Tumor; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Medical Oncology; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Recurrence; Skin Neoplasms; Tomography, X-Ray Computed | 2011 |
Response to the paper entitled clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Lower Extremity; Melanoma; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2011 |
Metastasis of malignant melanoma to common biliary duct demonstrated with F-18 FDG PET/CT.
Topics: Bile Duct Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.
Topics: Adenocarcinoma; Astrocytoma; Breast Neoplasms; Cell Line, Tumor; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Glucose; Glycolysis; Humans; Male; Melanoma; Neoplasm Proteins; Positron-Emission Tomography; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Radiopharmaceuticals; RNA, Messenger; RNA, Neoplasm | 2011 |
The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.
Topics: Aged; Aged, 80 and over; Ethmoid Sinus; Female; Fluorodeoxyglucose F18; Humans; Male; Maxillary Sinus Neoplasms; Melanoma; Middle Aged; Multimodal Imaging; Nasal Cavity; Nose Neoplasms; Paranasal Sinus Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
CT-guided percutaneous biopsy of a mass lesion in the upper presacral space: a sacral transneuroforaminal approach.
Topics: Biopsy; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lumbosacral Region; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Skin Neoplasms; Soft Tissue Neoplasms; Tomography, X-Ray Computed | 2012 |
Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs on patients with malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Lower Extremity; Melanoma; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Skin Neoplasms; Tomography, X-Ray Computed; Young Adult | 2011 |
Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Nodes; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Radiometry; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin; Skin Neoplasms | 2011 |
Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Nerve Growth Factors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tomography, X-Ray Computed | 2012 |
A case of primary leptomeningeal melanoma evaluated on FDG PET/CT.
Topics: Cauda Equina; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.
Topics: Adult; Aged; Aged, 80 and over; Extracellular Matrix Proteins; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Proteins; Positron-Emission Tomography; Retrospective Studies; S100 Proteins; Sensitivity and Specificity; Tomography, X-Ray Computed | 2011 |
Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases.
Topics: Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Tomography, X-Ray Computed | 2012 |
Navigation-assisted localisation and resection of subclinical metastatic malignant melanoma of unknown primary based on 18-fluorodeoxyglcose positron emission tomography computed tomography fusion imaging.
Topics: Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Middle Aged; Multimodal Imaging; Neck Dissection; Neoplasms, Unknown Primary; Positron-Emission Tomography; Radiopharmaceuticals; Scalp; Skin Neoplasms; Surgery, Computer-Assisted; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.
Topics: Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Topics: Animals; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Hydrolases; Melanoma; Mice; Positron-Emission Tomography; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Choline; Deuterium; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Kidney; Kinetics; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxidation-Reduction; Positron-Emission Tomography; Prostatic Neoplasms; Radioactive Tracers | 2012 |
Early [18F]fluorodeoxyglucose-positron emission tomography responses in metastatic melanoma: what do they mean?
Topics: Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Melanoma; Radionuclide Imaging; Skin Neoplasms; Sulfonamides; Vemurafenib | 2012 |
An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection.
Topics: Adult; Aged; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Queensland; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
It is never too late: ultra-late recurrence of melanoma with distant metastases.
Topics: Aged; Diagnosis, Differential; Fatal Outcome; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Significant head motion can cause either hypermetabolic or hypometabolic cerebral activity on 18F-FDG PET/CT.
Topics: Aged; Brain; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Head Movements; Humans; Hypesthesia; Male; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Ipilimumab-induced colitis on FDG PET/CT.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Colitis; Female; Fluorodeoxyglucose F18; Humans; Ipilimumab; Melanoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
[The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
Topics: Adult; Aged; Carcinoma; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Middle Aged; Multimodal Imaging; Neck; Neoplasms, Unknown Primary; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Medical Oncology; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2012 |
A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Topics: Adult; Aged; Disease Progression; Disease-Free Survival; Extremities; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Population Surveillance; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2012 |
Extrarenal retroperitoneal angiomyolipoma mimicking metastatic melanoma: CT and FDG PET correlation.
Topics: Adult; Angiomyolipoma; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Kidney; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2012 |
FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.
Topics: Adult; Aged; Cancer Vaccines; Dendritic Cells; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
The use of intraoperative PET probe to resect metastatic melanoma.
Topics: Adult; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Intraoperative Period; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2010 |
Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Small bowel metastases from melanoma: does videocapsule provide additional information after FDG positron emission tomography?
Topics: Adult; Aged; Capsule Endoscopy; Duodenal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Jejunal Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2012 |
Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Hexokinase; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Melanoma; Middle Aged | 2012 |
Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma.
Topics: Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma.
Topics: Adult; Aged; Body Burden; Choroid Neoplasms; Epidemiological Monitoring; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Monte Carlo Method; Multimodal Imaging; Neoplasms, Radiation-Induced; Positron-Emission Tomography; Radiation Dosage; Radiometry; Radiopharmaceuticals; Risk Assessment; Risk Factors; Tomography, X-Ray Computed; Whole Body Imaging; Whole-Body Irradiation; Young Adult | 2013 |
Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Single-Blind Method; Skin Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2014 |
[Primary malignant melanoma of the vagina].
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Vaginal Neoplasms | 2013 |
Cardiac and acoustic metastases in relapsing melanoma.
Topics: Female; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neuroma, Acoustic; Radionuclide Imaging; Recurrence | 2013 |
Ipilimumab in cancer patients: the issue of early metabolic response.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Dermatitis; Fluorodeoxyglucose F18; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2013 |
Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT.
Topics: Aged; Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Topics: Adult; Aged; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Nerve Growth Factors; Radionuclide Imaging; Radiopharmaceuticals; Regression Analysis; Reproducibility of Results; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms | 2002 |
[Malignant melanoma: diagnostic value of F-18 FDG positron emission tomography].
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
Endometrial carcinoma diagnosed by positron emission tomography: a case report.
Topics: Aged; Carcinoma; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasms, Multiple Primary; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection.
Topics: Adult; Aged; Disease Progression; Extremities; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Injections, Intravenous; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Recurrence; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Tomography, Emission-Computed | 2002 |
Enchondroma: a benign osseous lesion with high F-18 FDG uptake.
Topics: Adult; Chondroma; Chondrosarcoma; Diagnosis, Differential; Female; Femoral Neoplasms; Fluorodeoxyglucose F18; Humans; Hyalin; Melanoma; Neoplasm Staging; Neoplasms, Second Primary; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed; Whole-Body Counting | 2002 |
Incidental detection of primary breast carcinoma with a modified coincident camera in a patient with non-Hodgkin's lymphoma and melanoma.
Topics: Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Mastectomy, Segmental; Melanoma; Neoplasm Staging; Neoplasms, Multiple Primary; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Whole-Body Counting | 2002 |
18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
Topics: Adult; Aged; Aged, 80 and over; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasms; Radiopharmaceuticals; Recurrence; Sensitivity and Specificity; Skin Neoplasms; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Comparison of MR and PET imaging for the evaluation of liver metastases.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Retrospective Studies; Sarcoma; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Melanoma patients evaluated by four different positron emission tomography reconstruction techniques.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2003 |
Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2003 |
PET detection of melanoma metastases in lymph nodes.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2003 |
A new animal model for the imaging of melanoma: correlation of FDG PET with clinical outcome, macroscopic aspect and histological classification in Melanoblastoma-bearing Libechov Minipigs.
Topics: Animals; Disease Models, Animal; Fluorodeoxyglucose F18; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Skin Neoplasms; Swine; Swine Diseases; Swine, Miniature; Tomography, Emission-Computed | 2003 |
Incidental detection of pigmented villonodular synovitis on FDG PET.
Topics: Back; Bone Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Hip Joint; Humans; Incidental Findings; Melanoma; Middle Aged; Pelvic Neoplasms; Radiopharmaceuticals; Skin Neoplasms; Synovitis, Pigmented Villonodular; Tomography, Emission-Computed | 2003 |
Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs?
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Leg; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Skin Neoplasms; Tissue Distribution; Tomography, Emission-Computed | 2003 |
Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2003 |
Fluorodeoxyglucose positron emission tomography in the presence of cardiac metastases.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Incidental Findings; Lymphoma, Non-Hodgkin; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
Lymph node false-positive FDG-PET after recent surgery in primary melanoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2004 |
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
Topics: Adult; Diagnostic Imaging; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Neoplasm Metastasis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
A role for FDG-PET in the surgical management of stage IV melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide.
Topics: Diuretics; Female; Fluorodeoxyglucose F18; Furosemide; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
[Early detection of synchronous thyroid carcinoma and malignant melanoma by fluorodeoxyglucose positron emission tomography].
Topics: Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Thyroid Neoplasms | 2003 |
Melanoma metastasis to the testis demonstrated with FDG PET/CT.
Topics: Aged; Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Subtraction Technique; Testicular Neoplasms; Tomography, X-Ray Computed | 2004 |
Uptake of FDG in the area of a recently implanted bioprosthetic mitral valve.
Topics: Aged; Bioprosthesis; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Heart Valve Prosthesis; Humans; Melanoma; Mitral Valve; Prosthesis-Related Infections; Radionuclide Imaging; Radiopharmaceuticals; Solitary Pulmonary Nodule | 2004 |
Primary melanoma of the oesophagus well palliated by radiotherapy.
Topics: Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Palliative Care; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
Interest of F-18 fluorodeoxyglucose positron emission tomography in the evaluation of vaginal malignant melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Vaginal Neoplasms | 2004 |
Update of the FDG PET search strategy.
Topics: Abstracting and Indexing; Databases, Bibliographic; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Information Storage and Retrieval; Melanoma; Neoplasms; Positron-Emission Tomography; PubMed; Software; Subject Headings | 2004 |
Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Cervical Vertebrae; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Spinal Cord Compression; Spinal Cord Neoplasms; Surgical Procedures, Operative; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies.
Topics: Aged; Back Pain; Breast Neoplasms; Cellulitis; Diagnosis, Differential; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lumbar Vertebrae; Melanoma; Radionuclide Imaging; Radiopharmaceuticals; Soft Tissue Neoplasms; Staphylococcal Infections | 2005 |
Vaginal melanoma mimicking bladder FDG activity in a patient with chronic renal failure.
Topics: Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Kidney Failure, Chronic; Melanoma; Radionuclide Imaging; Radiopharmaceuticals; Urinary Bladder Diseases; Vaginal Neoplasms | 2005 |
Lower extremity schwannoma: F-18 FDG PET and MR demonstration.
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lower Extremity; Magnetic Resonance Imaging; Male; Melanoma; Neurilemmoma; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Topics: Adult; Aged; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2005 |
Solitary splenic metastasis in a patient with a malignant melanoma diagnosed with F-18-FDG PET scanning.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Scapula; Splenic Neoplasms; Tomography, X-Ray Computed; Whole-Body Counting | 2005 |
Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.
Topics: Animals; Biological Availability; Cell Proliferation; Cell Survival; Fluorodeoxyglucose F18; Glucose; Hexokinase; Humans; Melanocytes; Melanoma; Mice; Monosaccharide Transport Proteins; Positron-Emission Tomography; Risk Factors; Sensitivity and Specificity; Species Specificity; Tumor Cells, Cultured | 2005 |
Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) accumulation in melanoma cells: is FDG a substrate of multidrug resistance (MDR)?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Blotting, Western; Drug Interactions; Drug Resistance, Multiple; Fluorodeoxyglucose F18; Humans; Melanocytes; Melanoma; Positron-Emission Tomography; Probability; Reference Values; Risk Assessment; Sensitivity and Specificity; Tumor Cells, Cultured | 2005 |
Visualization of primary uveal melanoma with PET/CT scan.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Uveal Neoplasms | 2006 |
Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma.
Topics: Adult; Bone Marrow Neoplasms; Bone Neoplasms; Diagnosis, Differential; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Neoplasm Invasiveness; Neoplasms, Unknown Primary; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Mediastinal histoplasmosis: F-18 FDG PET and CT findings simulating malignant disease.
Topics: Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Histoplasmosis; Humans; Lung Neoplasms; Mediastinum; Melanoma; Middle Aged; Osteitis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2005 |
Metastatic melanoma to the heart.
Topics: Female; Fluorodeoxyglucose F18; Heart Neoplasms; Heart Ventricles; Humans; Melanoma; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Whole Body Imaging | 2005 |
PET/CT imaging: detection of choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2005 |
Whole body PET/CT for initial staging of choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Choroid Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Neoplasms; Tomography, X-Ray Computed | 2005 |
Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon.
Topics: Antiviral Agents; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Mediastinal Neoplasms; Melanoma; Middle Aged; Polyethylene Glycols; Positron-Emission Tomography; Recombinant Proteins; Sarcoidosis; Sentinel Lymph Node Biopsy | 2005 |
Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 3. Hoarseness caused by cancer metastasis to the vagus nerve.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Cranial Nerve Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Hoarseness; Humans; Melanoma; Tomography, X-Ray Computed; Vagus Nerve Diseases | 2005 |
The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Intraoperative Care; Male; Melanoma; Neoplasm Recurrence, Local; Photons; Pilot Projects; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Surgery, Computer-Assisted; Treatment Outcome | 2005 |
Increased F-18 FDG skeletal muscle uptake secondary to altered weight bearing and the use of crutches.
Topics: Adult; Crutches; Diagnosis, Differential; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Muscle, Skeletal; Pelvic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Weight-Bearing | 2005 |
Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Treatment Outcome | 2006 |
The clinical role of CT/PET in oncology: an update.
Topics: Colonic Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2005 |
Malignant lesions can mimic gastric uptake on FDG PET.
Topics: Adult; Diagnosis, Differential; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastric Mucosa; Humans; Melanoma; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Stomach; Stomach Neoplasms | 2006 |
Fluorodeoxyglucose positron emission tomography for melanoma staging: refining the indications.
Topics: Decision Making; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Preoperative Care; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2006 |
Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tomography, X-Ray Computed | 2006 |
Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2006 |
Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2006 |
Bilateral adrenal metastases from malignant melanoma: concordant findings on (18)F-FDG and (18)F-FDOPA PET.
Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms | 2006 |
Choroidal melanoma with hematogenous spread to the liver: F-18 FDG PET/CT findings.
Topics: Aged; Choroid Neoplasms; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Uveal Neoplasms | 2006 |
Deep venous thrombosis on F-18 FDG PET/CT imaging.
Topics: Aged; Femoral Vein; Fluorodeoxyglucose F18; Humans; Iliac Vein; Lymphoma, Non-Hodgkin; Male; Melanoma; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Radiopharmaceuticals; Thrombophlebitis; Tomography, X-Ray Computed | 2006 |
Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Skin Neoplasms; Survival Rate | 2006 |
Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma.
Topics: Acne Vulgaris; Adult; Back; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2006 |
18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Choroid Neoplasms; Eye Enucleation; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Necrosis; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2006 |
(18)F-FDG accumulations in primary malignant melanoma of the esophagus.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma?
Topics: Adult; Antineoplastic Agents; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Sentinel Lymph Node Biopsy | 2006 |
Futility of positron emission tomography and other modalities in the initial radiographic screening of patients with melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Medical Futility; Melanoma; Neoplasm Metastasis; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2006 |
FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Fluorodeoxyglucose F18; Infusions, Intra-Arterial; Lymphatic Metastasis; Melanoma; Melphalan; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Tear of plantar fascia and tibiocalcaneal ligament with positive F-18 FDG PET findings.
Topics: Ankle Injuries; Diagnosis, Differential; Fascia; Female; Fluorodeoxyglucose F18; Humans; Ligaments, Articular; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Soft Tissue Neoplasms | 2006 |
Gallbladder metastasis from malignant melanoma: diagnosis with FDG PET/CT.
Topics: Aged; Fluorodeoxyglucose F18; Gallbladder Neoplasms; Humans; Male; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Subtraction Technique; Tomography, X-Ray Computed | 2006 |
[Evaluation of efficacy and clinical impact of FDG-PET on patients with suspicion of recurrent cutaneous melanoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case Management; Combined Modality Therapy; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Positron-Emission Tomography; Predictive Value of Tests; Prevalence; Prostatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms; Unnecessary Procedures | 2006 |
[Iatrogenic lung microembolism detected by 18FDG PET/CT].
Topics: Adult; Diagnosis, Differential; Endothelium, Vascular; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Iatrogenic Disease; Injections, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Pulmonary Embolism; Radiopharmaceuticals | 2006 |
Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms; Whole Body Imaging | 2007 |
A surgical perspective on positron emission tomography.
Topics: Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Image Enhancement; Melanoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Thyroid Neoplasms; Tomography, X-Ray Computed | 2007 |
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Reference Standards; Skin Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging.
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Guanine; Herpesvirus 1, Human; Image Processing, Computer-Assisted; Luciferases; Luminescence; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine Kinase; Tomography, X-Ray Computed; Transplantation, Heterologous | 2007 |
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Medical Oncology; Melanoma; Middle Aged; Neoplasm Metastasis; Nerve Growth Factors; Positron-Emission Tomography; Reproducibility of Results; Risk; ROC Curve; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET.
Topics: Adolescent; Adult; Aged; Automation; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Melanoma; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Artifact on PET/CT secondary to FDG accumulation in a vaginal tampon.
Topics: Adult; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Menstrual Hygiene Products; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Small bowel invagination caused by intestinal melanoma metastasis: unsuspected diagnosis by FDG-PET/CT imaging.
Topics: Diagnosis, Differential; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Intestine, Small; Leg; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |
False positive 18F-FDG PET/CT due to gynaecomastia.
Topics: Breast Neoplasms; Diagnosis, Differential; False Positive Reactions; Fluorodeoxyglucose F18; Gynecomastia; Humans; Male; Melanoma; Middle Aged; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
F-18 FDG-avid sclerosing angiomatoid nodular transformation (SANT) of the spleen: case study and literature review.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Histiocytoma, Benign Fibrous; Humans; Hypertension; Legg-Calve-Perthes Disease; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Positron-Emission Tomography; Skin Neoplasms; Splenectomy; Splenic Neoplasms; Tomography, X-Ray Computed | 2007 |
Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging.
Topics: Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Thyroid Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2007 |
Whole body positron emission tomography in follow-up of high risk melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Whole Body Imaging | 2007 |
Localized nodular synovitis mimicking metastatic melanoma in a patient with metastatic melanoma on whole-body F-18 FDG PET/CT with MRI and pathological correlation.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Soft Tissue Neoplasms; Statistics as Topic; Synovitis; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, X-Ray Computed | 2007 |
Second cancers discovered by (18)FDG PET/CT imaging for choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Breast Neoplasms; Choroid Neoplasms; Diagnosis, Differential; Fatal Outcome; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Injections, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Radiopharmaceuticals; Retrospective Studies; Sigmoid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2007 |
Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Head; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Retrospective Studies; Skin Neoplasms; Tomography, X-Ray Computed | 2007 |
S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Nerve Growth Factors; Positron-Emission Tomography; Radiopharmaceuticals; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tomography, X-Ray Computed | 2007 |
FDG uptake in a rectal malignant melanoma.
Topics: Adult; Anus Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2007 |
Role of FDG-PET in the assessment of survival prognosis in melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Sex Factors; Time Factors; Tomography, Spiral Computed | 2007 |
Desmoplastic malignant melanoma evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography and sentinel lymph node biopsy.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Skin Neoplasms | 2008 |
Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of
Topics: Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Intraoperative Care; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Thigh; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2008 |
Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation.
Topics: Aged; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lip Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Neoplasms, Nerve Tissue; Radiopharmaceuticals; Tomography, Emission-Computed | 2008 |
Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma.
Topics: Adult; Aged; Aged, 80 and over; Conjunctival Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Positron-Emission Tomography; Radiography; Radioisotopes; Sensitivity and Specificity; Uveal Neoplasms; Whole-Body Irradiation | 2008 |
Findings of intramediastinal gossypiboma with F-18 FDG PET in a melanoma patient.
Topics: Fluorodeoxyglucose F18; Foreign-Body Reaction; Humans; Incidental Findings; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Surgical Sponges | 2008 |
Desmoplastic neurotropic melanoma in a patient with trigeminal neuralgia: FDG PET/CT and MRI.
Topics: Adult; Fibroma, Desmoplastic; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Melanoma; Orbital Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Trigeminal Neuralgia | 2008 |
Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Nerve Growth Factors; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Sensitivity and Specificity; Subtraction Technique; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The relationship between combined positron emission tomography/computed tomography and clinical and light microscopic findings in choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Choroid Neoplasms; Eye Enucleation; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Microscopy; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma.
Topics: Adolescent; Adult; Aged; Cicatrix; Costs and Cost Analysis; Deoxyglucose; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Ultrasonography | 1995 |
Detection of unsuspected metastasis in a melanoma patient with positron emission tomography.
Topics: Adult; Deoxyglucose; Female; Femoral Neoplasms; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Recurrence, Local; Tomography, Emission-Computed | 1995 |
Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines.
Topics: Bone Marrow; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Colony-Stimulating Factor; Male; Melanoma; Middle Aged; Tomography, Emission-Computed | 1995 |
Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Topics: Adult; Aged; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Tomography, Emission-Computed | 1995 |
Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Topics: Deoxyglucose; Feasibility Studies; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Pilot Projects; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 1993 |
FDG-PET screening for cerebral metastases in patients with suspected malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Breast Neoplasms; Child; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Melanoma; Middle Aged; Retrospective Studies; Sarcoma; Testicular Neoplasms; Tomography, Emission-Computed | 1996 |
1996 SNM annual meeting: medical problem solving.
Topics: Artifacts; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Colorectal Neoplasms; Contrast Media; Dementia; Deoxyglucose; Eye Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Genetic Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasms; Radioisotopes; Radiotherapy; Rhenium; Societies, Medical; Technetium; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission tomography.
Topics: Deoxyglucose; Ethmoid Sinus; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Maxillary Neoplasms; Melanoma; Middle Aged; Nasal Cavity; Nose Neoplasms; Paranasal Sinus Neoplasms; Time Factors; Tomography, Emission-Computed | 1996 |
Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.
Topics: Adult; Aged; Aged, 80 and over; Artifacts; Deoxyglucose; Exercise; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Intestines; Male; Melanoma; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Tissue Distribution; Tomography, Emission-Computed | 1996 |
Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells.
Topics: Cell Hypoxia; Deoxyglucose; Female; Fluorodeoxyglucose F18; Humans; In Vitro Techniques; Leucine; Melanoma; Methionine; Ovarian Neoplasms; Oxygen; Thymidine; Time Factors; Tomography, Emission-Computed; Tritium; Tumor Cells, Cultured | 1996 |
Quantification of serial tumor glucose metabolism.
Topics: Computer Simulation; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Models, Biological; Reproducibility of Results; Tomography, Emission-Computed | 1996 |
Normal thymic uptake of FDG on PET imaging.
Topics: Adolescent; Adult; Child; Child, Preschool; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Reference Values; Skin Neoplasms; Thymus Gland; Tomography, Emission-Computed | 1996 |
Glucose metabolism and pathological findings in uveal melanoma: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Cell Division; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Male; Melanoma; Middle Aged; Prognosis; Sensitivity and Specificity; Tomography, Emission-Computed; Uveal Neoplasms | 1996 |
[123I-alpha-methyltyrosine scintigraphy in malignant melanoma].
Topics: Adult; Aged; alpha-Methyltyrosine; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Melanoma; Methyltyrosines; Middle Aged; Neoplasm Metastasis; Thoracic Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1997 |
Malignant melanoma staging using whole-body positron emission tomography.
Topics: Aged; Animals; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 1998 |
Effectiveness of positron emission tomography for the detection of melanoma metastases.
Topics: Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Melanoma; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 1998 |
[Muscle uptake of 18FDG in positron emission tomography].
Topics: Antineoplastic Agents; Anxiety; Breast Neoplasms; Diazepam; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Muscle Contraction; Muscle Relaxants, Central; Muscle, Skeletal; Peripheral Nervous System Diseases; Radiopharmaceuticals; Skin Neoplasms; Tissue Distribution; Tomography, Emission-Computed | 1998 |
Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 1998 |
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenog
Topics: Animals; Blood Volume; Brain Neoplasms; Capillary Permeability; Cerebrovascular Circulation; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Fluorodeoxyglucose F18; Humans; Lymphokines; Melanoma; Mice; Neoplasm Proteins; Neovascularization, Pathologic; RNA, Antisense; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Planar coincidence scintigraphy and PET in staging malignant melanoma.
Topics: Adult; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 1998 |
[FDG-PET in the staging of malignant melanoma].
Topics: Contrast Media; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
False-negative FDG PET imaging in a patient with metastatic melanoma and ileal intussusception.
Topics: Adult; Animals; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Ileal Diseases; Intestinal Neoplasms; Intestine, Small; Intussusception; Liver Neoplasms; Melanoma; Tomography, Emission-Computed | 1999 |
Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Risk; Skin Neoplasms; Tomography, Emission-Computed | 1999 |
FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid.
Topics: Adenoma, Oxyphilic; Aged; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Melanoma; Neoplasms, Multiple Primary; Radiopharmaceuticals; Skin Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed | 1999 |
Correlation of CT-guided fine-needle aspiration biopsy of the liver with fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of metastatic hepatic abnormalities.
Topics: Biopsy, Needle; Fluorodeoxyglucose F18; Humans; Leiomyosarcoma; Liver; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Tomography, Emission-Computed | 1999 |
Use of [F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Mandibular Neoplasms; Melanoma; Mouth Neoplasms; Neoplasm Recurrence, Local; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma.
Topics: Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Radiopharmaceuticals; Reproducibility of Results; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
FDG positron emission tomography in melanoma.
Topics: Blue Cross Blue Shield Insurance Plans; Device Approval; Drug Approval; Evaluation Studies as Topic; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Melanoma; Outcome Assessment, Health Care; Radiopharmaceuticals; Technology Assessment, Biomedical; Tomography, Emission-Computed; United States; United States Food and Drug Administration | 2000 |
Positron emission tomography scanning in malignant melanoma.
Topics: Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma.
Topics: Adult; Aged; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Middle Aged; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
Topics: Abdomen; Adolescent; Adult; Aged; Diagnostic Imaging; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Mass Screening; Melanoma; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Radiopharmaceuticals; Retrospective Studies; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed; Ultrasonography; Whole-Body Irradiation | 2000 |
Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Melanoma; Models, Theoretical; Oxygen Radioisotopes; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
Combined 18F-FDG-FDOPA tumor imaging for assessing response to therapy.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed | 2001 |
Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography.
Topics: Aged; Diagnosis, Differential; Ear, External; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neck; Radiopharmaceuticals; Sarcoidosis; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2001 |
Elevated FDG uptake in the lactating human breast.
Topics: Adult; Breast; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lactation; Melanoma; Neoplasm Staging; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2001 |
Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Humans; Kinetics; Lung Neoplasms; Male; Melanoma; Middle Aged; Phosphorylation; Prognosis; Radiopharmaceuticals; Radiosurgery; Tomography, Emission-Computed | 2001 |
FDG-PET in the detection of gastrointestinal metastases in melanoma.
Topics: Adult; Aged; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume.
Topics: Fluorodeoxyglucose F18; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Radiography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
[Primary diagnosis of papillary thyroid carcinoma in the framework of staging of malignant melanoma with F-18 deoxyglucose using PET].
Topics: Carcinoma, Papillary; Fluorodeoxyglucose F18; Humans; Melanoma; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, Emission-Computed | 2001 |
FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Drug Therapy, Combination; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Likelihood Functions; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tumor Necrosis Factor-alpha; Whole-Body Counting | 2001 |
Nondetection of sentinel lymph node with lymphoscintigraphy as a result of massive malignant invasion shown by positron emission tomography.
Topics: Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Invasiveness; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography.
Topics: Adult; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Melanoma; Menstruation; Radiopharmaceuticals; Rectal Neoplasms; Tomography, Emission-Computed; Uterus | 2002 |
Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Citrates; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gallium; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Whole-Body Counting | 2002 |
[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
Topics: Colorectal Neoplasms; Decision Making; Fluorodeoxyglucose F18; France; Health Care Surveys; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Otorhinolaryngologic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Surveys and Questionnaires | 2002 |
[Diagnosis of metastasis of malignant melanoma in the thyroid gland with f18-FDG PET scan].
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed | 2002 |
[The role of PET scan in the diagnosis of malignant melanoma].
Topics: Adult; Aged; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Skin Neoplasms; Tomography, Emission-Computed | 2002 |
Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioma; Glucose; Humans; Kidney Neoplasms; Melanoma; Stereotaxic Techniques; Tomography, Emission-Computed | 1991 |
A comparison of 131I-labeled antibodies, 2-deoxy-2-[18F]fluoro-D-glucose and 68Ga-EDTA in the imaging of human tumor xenografts in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Colorectal Neoplasms; Deoxy Sugars; Deoxyglucose; Edetic Acid; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Iodine Radioisotopes; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Radionuclide Imaging; Transplantation, Heterologous | 1990 |
Metabolic imaging of uveal melanoma using positron emission tomography.
Topics: Aged; Choroid Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Radiography; Tomography, Emission-Computed | 1990 |